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1. Introduction 
Nitric oxide is an uncharged free radical abundant in nanomolar quantities and detected by 
measuring nitric oxide synthase (NOS). Nitric oxide is a gas highly reactive, short lived free 
radical generated enzymatically by NOS involved in diverse physiological (neurotransmission, 
immune system) and pathophysiological (tumor progression) mechanisms. Nitric oxide is a 
biological mediator for its role as EDRF (endothelial-derived relaxing factor) responsible for 
the regulation of blood vessel relaxation and blood pressure maintenance [Labet et al. 2009]. In 
recent years, inhibition of NOS gene expression has become a scientific interest to measure NO 
in tissues and synthetic NOS/NO inhibitors have revolutionized molecular imaging of tissues. 
Present chapter presents a journey from major mechanistic concepts to the detection of NO, 
NOS and their multimodal bioimaging applications with limitations.  
 Several genes involve in NOS enzyme for its synthase activity (NOS1, NOS2A, NOS3); 
oxidoreductase activity (NOS1, NOS2A, NOS3, NQO1); as positive regulators(HSP90AB1 
or HSPCB, INS); as negative regulators (DNCL1, GLA, IL10);other AKT1, ARG2, DDAH2, 
DNCL1, EGFR, GCH1, GCHFR genes  
 NO diffuses freely across cell membranes. It is short lived but combines with metallic 
aromatic ‘spin traps' to make stable compounds. NO acts in a paracrine or autocrine 
manner influencing only cells near its point of synthesis. 
 NO is synthesized within cells by a flavocytochrome enzyme NO synthase (NOS). The 
human contains 3 different NO synthases:  
 nNOS (NOS-1) is found in neurons (hence the "n"); iNOS (inducible NOS-2), triggered 
by inflammatory cytokines found in macrophages; and eNOS (NOS-3): constitutively 
distributed in the vascular endothelium lining the lumen of blood vessels, lung, and 
platelets (called constitutive NOS or cNOS) [Perrier, et al. 2009]. All types of NOS 
produce NO from arginine with the aid of molecular oxygen and NADPH as shown in 
following redox reaction and Figure 1. Inhibition of NOS gene expression in cells may 
detect NO [Nie et al.2008; Terashima et al. 2010].  
 NADH-diphorase stain the NOS expression to detect NO in tissues  
 NO is generated in vascular endothelium cells (NO plays role in the regulation of 
vascular tone), peripheral and central neurons (NO acts as synaptic neuronal 
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messenger) by three isoforms of NO synthase, endothelial, neuronal, and inducible 
form [Perrier, et al. 2009, Claudette, et al. 2005]. Detection and in vivo monitoring of NO 
is very difficult. Spin traps, fluorescent dyes, chemi/bioluminescent sensors detect and 
image NO by ESR,NMR,PET,US,and optical methods.  
 
 
Fig. 1. Redox potentials and direction of electron flow in nNOS enzyme action are shown. 
The electron flow in the NOS dimer goes via NADPHFADFMN in the reductase of one 
monomer to the haem iron in the oxygenase domain of a separate monomer. The redox 
potentials are poised thermodynamically to make this occur. The potentials for the two-
electron oxidation of NADPH and the one-electron oxidations of FADH2, FMNH2 and ferric 
haem are illustrated at the bottom of the Scheme, with the red arrows indicating the 
direction of electron flow. Note that given the variety of redox couples and the closeness of 
the FADH2 and FMNH2 potentials the detailed picture is more complex than that illustrated. 
For example the FMNH+/FMN couple has a redox potential of -49 mV and is likely to 
donate electrons to the high-potential ferric superoxide species to form the ferryl 
intermediate. Reduction of the FMN back to FMNH+ would then require an electron from 
FMNH+. Adapted from Alderton, et al. 2001. 
 Mapping the distribution of NO generation or formation of stable spin-trapping species at 
different locations in tissues or organs by in vivo perfusion (3D visualization of NO 
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structural-functional or conformational dynamics as switch OFF and ON) may allow us 
to understand the real physiological function of NO gas or ionic form under different 
tissue physiological conditions [Thatte et al. 2009]. Using in vivo nitric oxide direct 
detection by stabilizing NO with suitable spin-trapping reagents is a challenge to estimate 
the in vivo NO concentration by MRI techniques [Hong et al. 2009; Sari-Sarraf, et al. 2009; 
Liu, et al. 2009; Ny et al. 2008; Fujii, et al, 2007; Vandsburger, et al.2007; Samouilov et al. 
2007; Flögel, et al. 2007; Bobko, et al. 2005; Day, et al. 2005; Waller, et al. 2005; Sirmatel, et 
al. 2007; Itoh, et al. 2004; Berliner, et al. 2004; Haga,et al. 2003; Li, et al. 2003; Hsiao, et al. 
2008; Kuppusamy, et al. 2001; Fichtlscherer, et al. 2000; Fujii,et al.1999; Fujii, et al. 2002].  
 Other nitric oxide bioimaging technique is flourimetry using fluorescent biomarkers in 
EPR spectroscopy [Kojima, et al.2001; Fuji, et al.1997; Yoshimura, et al. 1996]. Our 
immediate focus is to highlight the existing multimodal mechanisms of NO sensitive 
MRI/EPR signal generation using NOS enzyme expression inhibitors and biosensors to 
map cellular events. 
1.1 Nitric oxide as a second messenger in cellular signaling 
Nitric oxide signal transduction through induced-nitric-oxide modifications relies on the 
system of Cys-based posttranslational modifications. Accordingly, S-nitrosylation of 
proteins plays an essential role in downstream cascades (Do et al., 1996). Nitric oxide exerts 
an ubiquitous influence on cellular signaling in large part by means of S-
nitrosylation/denitrosylation of protein cysteine residues. S-NO undergo a regulated post-
translational protein modification specific to NO-derived effects. These NO-dependent 
modifications influence protein activity, protein-protein interactions, and protein location. S-
nitrosylation thus serves as the prototypical redox-based signal (Janssen-Heininger et al., 
2008). S-Nitrosylation has been implicated in transmitting signals downstream of all classes 
of receptors, including G-protein-coupled receptor (GPCR), receptor tyrosine kinase, tumor 
necrosis factor, Toll-receptors, and glutaminergic receptors, acting locally within subcellular 
signaling domains as well conveying signals from the cell surface to intracellular 
compartments, including the mitochondria and the nucleus (Janssen-Heininger et al., 2008). 
Cell signaling through S-nitrosylation is useful tool in signaling transduction for: 
1. Temporal regulation of response through a rapid and controlled stimulation; 
2. The existence of motifs within proteins that provides S-nitrosylation specificity; 
3. Colocalization of target proteins with a source of NO; 
4. Reversibility of protein S-nitrosylation; 
5. Enzymatic control of S-nitrosylation through the action of S-nitrosoglutathione 
reductase (Janssen-Heininger et al., 2008). 
1.2 Why inhibition of NOS expression as bioimaging of NO technique  
Mapping the distribution of NO generation at different locations in different tissues and 
organs by in vivo perfusion reveals the physiological function of NO (gas or ionic form) in 
different tissue physiological conditions [Thatte, et al.2009]. Major nitric oxide imaging 
techniques utilize mapping NO in tissue using NO specific imaging contrast agents sensitive 
to fluorescence, magnetic resonance and electron spin resonance. Imaging in vivo physical 
properties of tissue cells such as cell calcium signaling and NO-biomarker is new way by 
proton magnetic resonance techniques to achieve nanomolar range of nitric oxide mapping 
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without any toxic effects[Thatte, et al.2009, Hong et al.2009]. Fluorescent nitric oxide 
cheletropic traps are currently available choices in nitric oxide imaging but all of these have 
pitfalls of causing neurotoxicity [Reif et al.2009]. In this chapter, we display evidence of the 
NO sensitive fluorescent probes as cell calcium signaling indicator and possibility of NO 
specific perfusion MRI tool to visualize physiological nanomolar dynamics of NO in living 
cells and tissues up to the detection limit of 0.1 nM. The cell signaling indicators such as 
intracellular calcium revealed that ~1 nM of NO was enough to detect apoptosis events such 
as caspase 3 activation [Li et al.2009].  
 
Fig. 2. Domain structure of human nNOS, eNOS and iNOS(on left), Overall reaction 
catalysed and cofactors of NOS(on right). Adapted from Alderton, et al. 2001. 
1.2.1 Feasibility of NOS expression inhibitors as imaging Contrast Agents  
NO is a gaseous and highly active neuronal messenger, short lived free radical generated 
enzymatically by NOS in the brain[ Perrier et al.2009]. NOS is a flavocytochrome that is 
constitutively distributed in the vascular endothelium, brain, lung, and platelets (called 
constitutive NOS or cNOS), but is also found as an inducible form (called inducible NOS or 
iNOS) in many cells and organs, triggered by several factors such as inflammatory cytokines 
[Claudette et al.2009]. However, NOS is abundant in three isoforms cNOS, iNOS, eNOS as 
shown in Figure 2. NOS undergo dimerization in presence of BH4 or heme or arginine binding 
sites. Different roles of flabin, heme, pterin cofactors in NOS are described in detail [Alderton, 
et al. 2001, Matter et a. 2004]. Authors reviewed NOS activity regulation by calmodulin, 
phosphorylation, protein inhibitors of NOS(PIN), heat shock protein 90(Hsp 90), 
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myristoylation, palmitoylation, caveolin, at different domain located in NOS or spilce variants: 
nNOSǃ and nNOSǄ, nNOSµ, nNOS-2, iNOS/eNOS splice variants. However, cross-activities 
of all three isoforms of NOS and their dependence on calcium, common locations have put 
challenge to specificity and gave way to a new way of specific NO/NOS inhibitor compounds. 
In recent years, NOS gene expression and its regulation have got attention for two reasons: 
 NOS gene expression can be stained, imaged for multimodal molecular imaging 
 The NOS inhibitors inhibit NOS as potent anti-inflammatory agents in recent years.  
 Visualization of NOS inhibition is believed to serve as in vivo or in vitro biomarkers of 
the proinflammatory status of NOS inhibitors or in vivo proinflammation bioimaging of 
tissues. 
Some examples of NOS ihibitors are given below. 
1.2.2 NOS Inhibitors 
NOS inhibition occurs at arginine site, tetrahydrobiopterin site, pteridine site, and heme 
domain by partially selective or highly selective inhibitors [Alderton, et al. 2001, Matter et a. 
2004]. Excellent information of binding site interactions of NOS with relationships at 
different sites is available [Alderton, et al. 2001, Matter et al. 2004]. To understand better the 
NOS inhibitor structural-activity relationship, X-Ray analysis, 3D QUSAR, comparative 
molecular field analysis (CoMFA) analysis, GRID/PCA interpretations have enhanced the 
scope of NOS in pharmacology as shown in Figures 3,4,5 [Matter et al.2004]. There are array 
of NOS inhibitors described in the literature as drug testing tools. Table 1 shows efficacy of 
some of these in inhibiting the three human NOS isoforms.. Of these the most widely used 
have been l-NMMA, l-NNA and its methyl ester prodrug (NG-nitro-l-arginine methyl ester, 
`l-NAME' and aminoguanidine. However, inhibitors show pitfalls on selectivity to NOS, 
types of interactions with iNOS and nNOS isoforms. Selective NOS inhibitors may be 
selective in the physiological range (l-arginine concentration etc). Inhibitor agents with 10-
50-fold selectivity are useful as `partially selective inhibitors.  
 
inhibitor 
IC50 (µM) Selectivity (fold) 







L-NNA* 3.1 0.29 0.35 0.09 0.11 1.2 
L-NMMA 6.6 4.9 3.5 0.7 0.5 0.7 
7-NI* 9.7 8.3 11.8 0.9 1.2 1.4 
ARL17477* 0.33 0.07 1.6 0.2 5 23. 
Aminoguanidine* 31 170 330 5.5 11 1.9 
L-NIL 1.6 37 49 23. 49. 1.3 
1400W 0.23. 7.3 1000 32. 4000*. 130* 
GW273629 8.0. 630 1000 78. 125*. 1.6* 
GW274150 1.4. 145 466 104. 333 3.2 
The data shown are for inhibition of the human NOS isoforms in the presence of 30 µM L-arginine at 37 
°C over 15 min after a 15 min pre-incubation with inhibitor under turnover. The data serves as 
progressive inhibitory mechanisms for the NOS assay. Data are from Young et al. 2000.  
Table 1. Selectivity of inhibitors of NOSs is compared for different inhibitors 
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Fig. 3. Contour maps for NOS-I comparative molecular field analysis (CoMFA) analysis with 
a 4-amino-pteridine inhibitor.A: Steric contour map, green contours indicate sterically 
favored regions, yellow contours indicate unfavored areas. B: Samethan, A: with NOS-I 
binding site. C: Electrostatic contour map, blue contours refer to regions, where negatively 
charged substituents are unfavorable, red contours indicate regions, where negatively 
charged substituents are favorable. D: Same as C with NOS-I binding site. Reproduced with 
permission from Matter et al. 2004. 
 
Fig. 4. A: Score plot from GRID/principal componentanalysis (PCA) based on13 
conformations and 3NOS isoforms. B: SuperpositionofNOS-III (1nse, blue) toNOS-IX-ray 
(magenta) andhumanbrainNOS-I (homology, purple).C:Scoreplot fromGRID/CPCA for 
hydrophobic interactions (GRID dry probe). D:GRID/CPCA differential plots highlighting 
differences between NOS-I/NOS-II and NOS-I/NOS-III.Favorable interactions 
toachieveNOS-I isoformselectivities are shownincyancontours, unfavorable interactions are 
displayed in yellow with respect to H4Bipfromthe NOS-III1nse X-ray structure. Reproduced 
with permission from reference [Matter et al. 2004] 
www.intechopen.com
Inhibition of Nitric Oxide Synthase Gene Expression:  
In vivo Imaging Approaches of Nitric Oxide with Multimodal Imaging 
 
121 
The mechanistic nature of three human NOS isoforms was expressed in the baculovirus 
expression system, and cell lysates as the enzyme source. iNOS potency and selectivity 
underestimates progressive inhibition of iNOS but not eNOS or nNOS; e.g. for 1400W the 
steady-state values of iNOS IC50 and selectivity have been estimated to be 0.1 µM, 250-
fold (versus nNOS) and 5000-fold (versus eNOS) as reported by Young, et al. 2000. Highly 
selective compounds of over 50- or 100-fold selectivity, inhibit the NOS activity of a single 
isoform without affecting others. They have potential as selective therapeutic agents 
without side effects. Recently, 7-nitroindazole (7-NI) was reported as non selective nNOS 
inhibitor, of isolated NOS enzyme (Table 1). 7-NI showed inhibition of nNOS independent 
of increases in blood pressure but showed eNOS-dependent celltype specificity (neuronal 
verus endothelial), intracellular BH4 concentration, or depending on specific cellular 
transport or metabolism [Handy, et al. 1998]. All three NOS isoforms can be expressed in 
neurons and both eNOS and iNOS in endothelial cells. Cell-type specificity is clearly a 
very distinct phenomenon from isoform selectivity. Other pitfall is particular dose. For 
example, in humans, the non-selective NOS inhibitor l-NMMA causes a five-fold increase 
in vascular resistance with only a 10% change in blood pressure, because of reflex 
decreases in cardiac output 185±187 [Ross et al. 1998] Suppression of inhibitor-induced 
plasma nitrate (mediated predominantly by iNOS) and no effects on blood pressure has 
led to inhibitors as non selective, e.g. S-ethylisothiourea [Raman, et al. 1998]. Selectivity 
for iNOS versus eNOS distinct enzyme targets is another pitfall. Time-dependent NOS 
inhibition in assessing efficacy and selectivity of NOS inhibitors were first reviewed by 
Bryk and Wolff, 1999.  
1.2.3 NOS inhibitor interactions with the NOS enzymes 
Inhibitors of NOS have been described which interact with the NOS enzymes in a variety of 
ways: different sites, differing time- and substrate-dependence, and mechanism of 
inhibition. 
L-Arginine site inhibitors identified so far as competitive with the substrate L-arginine 
binding at the arginine-binding site inhibitors (aminoguanidine, S-ethylisothiourea, 
thiocitrulline) [Raman, et al.1998].  
Mechanism-based inhibitors of iNOS require active enzyme and NADPH substrate to 
permit inhibition to proceed through multiple enzyme covalent modification by a 
complex formation pathway: EI-EI* complex where E is iNOS, I is the inhibitor, EI is the 
initial non-covalent complex and EI* is a modified complex, either with a conformational 
change to tight binding or with covalent changes to the enzyme, inhibitor or both. The 
interactions of some of these pterin-site inhibitors with NOS reveal unexpected 
complexity. An example of a mechanism based iNOS inhibition was cited by 
aminoguanidine [197±199] and by the acetamidine inhibitors N-ǂ-iminoethyl-l-ornithine 
(l-NIO) and N'-iminoethyl-lysine (l-NIL) [200±203], GW273629 (S-[2-[(1-iminoethyl)-
amino]ethyl]-4,4-dioxo-l-cysteine) and GW274150 (S-[2-[(1-iminoethyl)amino]ethyl]-l-
homocysteine) (see Table 1). Heme-binding inhibitors have been shown to bind with 
each NOS monomer, one to the haem iron and one to the arginine-binding region (Glu ) in 
competition with CaM. These compounds affect the assembly of iNOS monomers into 
active dimer inhibiting the dimerization [Sennequier, et al. 1999]. A class of substituted 
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pyrimidine inidazoles have been identified which inhibit dimerization of iNOS during its 
synthesis and assembly.  
1.2.4 Flavoprotein and CaM inhibitors 
A range of flavoproteins (e.g. diphenylene iodonium) or CaM (e.g. trifluoperazine) has been 
shown to inhibit NOS. NOS inhibitors display selectivity of their isoforms as partially 
selective, highly selective. 
Partially and highly isoform-selective NOS inhibitors 
Identification of selective inhibitors of iNOS and nNOS "100-fold selectivity for iNOS versus 
eNOS are reported [Anon, 1999a, 1999b]. Partially-selective nNOS inhibitor amino acids for 
nNOS versus eNOS and iNOS were reported. For example, S-ethyl- and S-methyl-1-
thiocitrulline, vinyl-l-NIO showed timedependent inhibition of nNOS with significant 
selectivities versus isolated eNOS and iNOS enzymes [Babu and Griffith, 1998]. Other 
partially-selective iNOS inhibitors such as acetamidine-containing analogues of arginine, l-
NIO and l-NIL have been widely used to probe the effects of iNOS inhibition. For example, 
some 2-iminohomopiperidines and 2-iminopyrrolidines with high (100±900-fold) selectivity 
for iNOS versus eNOS, but similar potency was observed on iNOS and nNOS (1±13-fold 
selectivity), with dual action iNOS-nNOS inhibitors. 
Highly-selective iNOS inhibitors 
The `highly selective ' iNOS inhibitors versus eNOS are mostly bis-isothioureas. Of these, S,S-
[1,3-phenylene bis-(1,2-ethanediyl)bis-thiourea (`PBITU') is an l-arginine-competitive, rapidly 
reversible inhibitor of human iNOS with a Ki of 47 nM, and a selectivity (in Ki terms) of 190-
fold versus eNOS showing substrate-binding sites of full-length human iNOS and eNOS in 
solution or in cells and tissues. Inhibition of human iNOS by 1400W was competitive with l-
arginine, NADPH-dependent either an irreversible, or reversible. Mechanism-based inhibitor 
action was reported as Kd value %7 nM and steady-state selectivity against eNOS and nNOS of 
5000 and 250-fold respective effects on vascular leakage [Lazlo, et al.1997]. GW273629 and 
GW274150 are two novel NOS inhibitors for iNOS versus both eNOS and nNOS. Both are 
sulphur-substituted acetamidine amino acids acting in competition with l-arginine as 
NADPH-dependent, whereas the inhibition of human eNOS and nNOS is rapidly reversible. 
The heme-binding substituted pyrimidine imidazoles inhibit assembly of active dimeric iNOS 
during its synthesis. It will be interesting to see what the pharmacology and utility of such 
compounds will be, and whether other compound series are discovered with this NOS 
inhibition mechanism of action. 
1.3 The pharmacological inhibition of inducible nitric-oxide synthase (iNOS) gene 
expression 
Presently, inhibition of NOS gene expression approach is used in testing inhibitors of 
pharmacological value. In past, inhibition of NOS was ideal assay to measure less stable NO 
in tissues but less specificity of NOS was discouragement and spin trap agents have 
emerged as a new approach of detection and measurement of NO in both in vivo and in 
vitro assays and bioimaging. Some examples of NOS inhibitors are cited in following 
section. 
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1. AMP Kinase protein kinase induced inhibition of inducible nitric-oxide synthase (iNOS) 
Inducible NOS inhibition in endotoxic shock in chronic inflammatory states was 
observed in several cell types (myocytes, adipocytes, macrophages) and primarily 
resulted from post-transcriptional regulation of the iNOS protein. Best example is 
inhibition of inducible nitric oxide synthase by activators of AMP activated protein 
kinase to explain a new mechanism of insulin sensitizing drug action [Pilon, et al.2004].. 
Inflammatory cytokines and LPS trigger the iNOS transcription through a complex 
network of intracellular pathways including NF-κB, Janus kinase/signal transducers 
and activators of transcription, and mitogen-activated AMPK protein kinase by 
reducing the transcription of iNOS and mRNA expression [Blanchette et al. 2003]. 
AMPK switches off protein synthesis either through suppression of the mTOR-p70S6 
kinase pathway or by direct activation of eukaryotic elongation factor 2 kinase, 
resulting in the phosphorylation and inactivation of eukaryotic elongation factor 2 
[Horman et al. 2002]. AMPK reduces iNOS protein content by promoting its 
ubiquitination, required for targeting iNOS through the proteasome proteolysis 
pathway [Kolodziejski et al.2002].  
2. Expression of exogenous Kalirin in pituitary cells dramatically reduces iNOS inhibition 
of ACTH secretion. Kalirin inhibits iNOS activity by affecting iNOS homodimerization, 
which is required for iNOS activity. Thus Kalirin may play a neuroprotective role 
during inflammation of the central nervous system by inhibiting iNOS activity 
[Ratovitski, et al. 1999].  
3. N5-(Iminoalkyl)- and N5-(Iminoalkenyl)-ornithines (VNIO) and several L-VNIO analogs 
showed minor structural changes to produce inhibitors either iNOS-selective or 
nonselective [Bretscher et al. 2003]. Furthermore, derivatives having a methyl group 
added to the butenyl moiety of L-VNIO and L-VNIO derivatives display slow-on, slow-
off kinetics rather than irreversible inactivation. These results elucidate isoform-
selective inhibition by L-VNIO and may provide information useful in rational design 
of isoform-selective inhibitors. [Bretscher, et al. 2003]  
4. Constitutive and inducible isoforms of NOS are inhibited by S-alkyl-L-thiocitrullines 
with n-alkyl groups of any one carbon. The NOS inhibition is reversible, stereoselective, 
and competitive with L-arginine[Narayanan, et al. 1995].  
5. Autoinhibition of endothelial NOS was reported by presence of an electron transfer 
control element in the NOS. [Nishida, et al. 1999]. Investigators examined the role of 
the insert in its native protein context by deleting the insert from both wild-type 
eNOS and from chimeras obtained by swapping the reductase domains of the three 
NOS isoforms. The Ca2+ concentrations required to activate the enzymes decrease 
significantly when the insert is deleted, consistent with suppression of autoinhibition. 
Furthermore, removal of the insert greatly enhances the maximal activity of wild-type 
eNOS, the least active of the three isoforms. Despite the correlation between 
reductase and overall enzymatic activity for the wild-type and chimeric NOS 
proteins, the loop-free eNOS still requires CaM to synthesize zNO. However, the 
reductive activity of the CaM-free, loop-deleted eNOS is enhanced significantly over 
that of CaM-free wild-type eNOS and approaches the same level as that of 
CaMbound wild-type eNOS. Thus, the inhibitory effect of the loop on both the eNOS 
reductase and zNO-synthesizing activities may have an origin distinct from the loop’s 
www.intechopen.com
 
Enzyme Inhibition and Bioapplications 
 
124 
inhibitory effects on the binding of CaM and the concomitant activation of the 
reductase and zNO-synthesizing activities. 
6. A mechanism was reported as Ca2+ triggers cross-talk signal transduction between 
CaM kinase and NO and CaM-K IIa phosphorylating nNOS on Ser847, which in turn 
decreases the gaseous second messenger NO in neuronal cells by 
Calcium/Calmodulin-dependent Protein Kinase IIa in NG108-15 neuronal Cells. 
[Komeima, et al. 2000].   
7. Nitric oxide (NO) is moderately produced under control of iNOS gene expression. In 
recent years, scientists solved the problem of visualizing very unstable NO by mapping 
iNOS inhibition using gene expression array, in vivo nitric oxide direct detection (by 
stabilizing NO with suitable spin-trapping reagents), bioluminesence and MRI 
techniques to estimate in vivo NO concentration [Hong et al. 2009]. New approaches are 
in the direction of multimodal bioimaging iNOS gene expression and NO bioimaging as 
biomarkers. Success depends on NOS gene sensitive MR relaxation signal in cells and 
specificity to inflammation [Nie et al.2008; Terashima et al. 2010].  
2. NO inhibitors in imaging  
Major nitric oxide imaging techniques utilize mapping NO in tissue using NO specific 
imaging contrast agents sensitive to fluorescence, magnetic resonance and electron spin 
resonance. Recently, focus is diverted towards imaging in vivo physical properties of tissue 
cells such as cell calcium signaling and NO-biomarker based proton magnetic resonance 
techniques to achieve nanomolar range of nitric oxide mapping without any toxic 
effect. Fluorescent nitric oxide cheletropic traps are currently available choices in nitric oxide 
imaging but all of these have pitfalls of causing neurotoxicity [Reif, et al.2009]. In following 
sections, we put evidence of the NO sensitive fluorescent probes as cell calcium signaling 
indicator in tissues and possibility of NO specific perfusion MRI tool to visualize 
physiological nanomolar dynamics of NO in living cells up to the detection limit of 0.1 nM. 
The cell signaling indicators such as intracellular calcium revealed that ~1 nM of NO was 
enough to detect apoptosis events such as caspase-3 activation [Green, 1998, Nagata, 1997, 
Kwon et al.2009]. Furthermore, the possibility of superparamagnetic iron oxide nanoparticle 
bound complexes serve as MRI imaging contrast agents based on dephasing contrast. The 
iron oxide chelates are still in active evaluation phase to test their toxicity. The nanomolar 
range of basal endothelial NO appears to be fundamental to vascular homeostasis, hypoxia, 
apoptosis and inflammation.  
 different contrast mechanisms and contrast characteristics of known nitrosyl-iron 
complexes display possibility of potential multimodal MRI and EPR probes specific to 
NO with examples of dithiacarbamates and Fe(MGD)2 complexs in different 
applications.  
 fMRI detects the interaction of paramagnetic species with NO in blood but possibility is 
still controversial. We review different applications of NO bioimaging. 
2.1 Dithiacarbamates, LPS and MGD complexes for bioimaging of NO  
In following sections we highlight the existing mechanisms and description to NO sensitive 
signal generation. Existing mechanisms of NO sensitive signal generation are explored by 
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MRI and fluorescence arising out from paramagnetic metals, dithiacarbamates or 
lipopolysaccharides complexes. The mechanisms depend on three approaches:  
 Use of paramagnetic metals (SPIO) in MRI and dithiacarbamates (DTC) or 
lipopolysaccharides (LPS) complexes sensitive to MRI and fluorescence effects;  
 Use of cytochrome proteins sensitive to EPR effect;  
 Use of NO synthase inhibitors to measure the reduced NO concentrations for 
fluorometry and blood oxygen sensitivity to reduced NO concentrations.  
The following sections are focused on dithiacarbamates in fluorometry and less known 
imaging contrast agents in MRI to image nitric oxide in tissues. 
The first evidence of dithiacarbamates (DTC) reported them as electron Fe(II)-chelate spin 
trap agents. Examples are N-methyl-D-glucamine dithiocarbamate (MGD), (MGD)2-Fe(II)-
NO and NO-Fe-DTC metal complexes as multimodal imaging agents. These were initially 
verified for EPR with possibility of visualizing the radical distribution by MR images 
[Kubrina, et al.1992]. The (MGD)2-Fe(II)-NO complex enhanced the contrast in the vascular 
structures such as hepatic vein and inferior vena cava. The paramagnetic NO-Fe-DTC metal 
complex is also a potential MRI signal enhancer and acts as contrast agent. These contrast 
agents showed the magnetic relaxation changes of neighboring protons to visualize the NO 
generated in living animal tumors [Jordan et al. 2000]. Other contrast enhancement effect 
showed an impact of short NO exposure to hemoglobin during MRI signal recording as 
source of in vitro MRI and in vivo functional MRI (fMRI) [Di Salle, et al. 1997]. fMRI signal 
intensity of venous blood in T1-, T2-, and T2*-weighted images proportionately changed 
with NO real-time generation in brain. Later, different approaches of blood hemoglobin and 
NO interaction were attempted to monitor fMRI signal sensitive to NO: mainly metHb and 
NO-Hb enhanced the MRI signal intensity. These observations suggested a blood flow-
independent effect and less utility [Di Salle, et al. 1997]. Still it is hope that NO sensitive 
fMRI techniques can detect slow epithelial intracellular processes such as metabolic 
integrity, vascular tonicity, stress, shear and inflammatory effects at early stages of the 
disease processs, allowing precise monitoring of onset in intact biological systems at cellular 
level. Other approaches are also emerging to use NO biosensors for multimodal 
imaging. Currently, use of fMRI as a non-invasive NO sensitive technique has emerged as 
potential and remarkable tool to detect apoptosis in vivo. The NO sensitive fMRI techniques 
can detect slow epithelial intracellular processes such as metabolic integrity, vascular 
tonicity, stress, shear and inflammatory effects at early stages of the process, allowing the 
onset in intact biological systems, providing a useful tool for monitoring at cellular level. 
2.2 The source of intracellular NO and metabolic integrity- feasibility of MRI 
The nitric oxide is released from the L-arginine in tissue along with molecular oxygen in the 
oxidative L-arginine degradation reaction of L-arginine pathway catalyzed by either of any 
three different NO synthase (NOS) isoenzymes. NO controls the intracellular redox state in 
tissue and protects the metabolic integrity in two ways [Kuppusamy, et al. 1994]. First, 
anions and cations in intracellular space or cellular redox state prevent apoptosis for 
example, NO in hepatocytes, neurons, glial cells and fibroblasts controls the release of 
mitochondrial apoptogenic factors and induces apoptosis by activation of caspases 
[Hortelano, et al.2005 ]. Second, peroxynitrites accumulate as product of nitric oxide and 
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superoxide anion. Peroxynitrites promote apoptosis through the indirect activation of 
caspases [Kuppusamy, et al. 1994, Hortelano, et al.2005]. However, all these approaches are 
still invasive to evaluate apoptosis. 
Overproduction of nitric oxide and imaging the NO accumulation due to neurotoxicity was 
reported in neurological disorders or neurodegeneration. The reason of neurotoxicity was 
reported due to NO reactive oxidative properties in tissue [Caramia, et al. 1998]. This 
approach was reported not to solve the purpose of in vivo functional monitoring but NO 
properties indicated the state of tissue and follow-up of dynamic status of 
neurodegenerative factors in brain [Caramia, et al. 1998]. In other application of NO 
bioimaging to detect apoptosis, T2 weighted maps from control vs GSNO treated and 
z.VAD treated animals exhibited hyperintense areas perhaps due to toxicity of NO on the T2 
maps while z-VAD treated animals showed small lesion areas due to reduced NO toxicity. 
The response of z-VAD injection was presumed as reduced toxicity due to caspases and NO-
dependent apoptosis. These authors explained that GSNO increased T2 intensity 25% while 
z-VAD reduced this MRI signal [Komarov, et al. 1995]. These classic reports indicated that 
T2 hyperintensities on MRI positively offer the possibility of in vivo evaluation of cell death 
at different locations in whole tissues undergoing apoptosis. The apoptosis is also a major 
mechanism in brain neurodegeneration and post-myocardial infarction heart [Caramia, et al. 
1998]. However, this approach seems as potential tool of functional imaging in near future 
to monitor the therapeutic intervention of new drugs to reduce neurodegeneration[ 
Kuppusamy, et al. 1994, Hortelano, et al.2005, Foster, et al. 1998]. Currently, non-invasive 
NO sensitive techniques are big hope as potential and remarkable tools to detect apoptosis 
in vivo.  
Initial studies on NO with iron-dithiocarbamate complexes had succeeded in direct 
detection of NO in mice by whole body electron paramagnetic resonance spectroscopy 
(EPR) at the L-band [Fujii, et al. 1997, Komarov, et al. 1995] with new possibilities by 
Magnetic Resonance Spectroscopy [Reif, et al. 2009, Li, et al. 2009]. Several authors 
demonstrated the feasibility of EPR imaging in visualizing free radical distributions in vivo 
at low resolution where the intrinsic line width of the radical is large, such as the spin-
trapped NO [Yoshimura, et al. 1996, Kubrina, et al. 1992, Foster, et al. 1998]. This drawback 
of low resolution caught attention for feasible MRI contrast agents, such as stable (N-methyl-
D-glucamine)2-Fe(II)-NO complex to generate better resolution. The complex has a much 
longer in vivo half-life than most (stable) nitric oxide derived compounds. Recently N-
methyl glucamine iron complexes have shown greater affinity with NO to make (MGD)2-
Fe(II)-NO complex useful for in vivo NO measurements by EPR [Caramia, et al. 1998]. In 
recent years, the art of MRI combined with NO spin trapping mechanism was evaluated as 
feasible method of mapping the distribution of NO spin-trap complex in animals with 
possibility in clinical use. In following section, our design of ultrafast MRI protocol is 
described using NO/NOS sensitive biosensor complexes for use at 21-Tesla MRI 
microimager.  
2.3 Approach of stable NO sensitive lipopolysaccharides (LPS) as feasible imaging 
complexes  
The LPS serves as encaged bag holding contrast agent. The LPS based NO imaging 
approach has following presumptions:  
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 spin-trapped NO is stable in intracellular tissue environment;  
 NO-LPS contrast enhancement properties are MRI visible;  
 NO-LPS complex is stable in tissues and organs; and  
 simultaneous visualization and mapping of NO free radicals are possible by MRI.  
The routine method of LPS injected animals after 6 hours of (MGD)2-Fe(II) injection, usually 
serve as experimental model of subsequent MRI detection and visualization of NO 
generated in animals. It was confirmed by using a specific NOS inhibitor N-monomethyl L-
arginine (L-NMMA) [Fujii, et al. 2007]. The observations indicated that the suppressed NO 
levels were proportional to NO sensitive LPS concentration independent of (MGD)2-Fe(II)-
NO contrast agent [Fujii, et al. 2007]. Next issue of feasibility and stability of (MGD)2-Fe(II)-
NO imaging contrast agent was major breakthrough reported in model systems to generate 
EPR and MRI signals. It is established that the NO complex (MGD)2-Fe(II)-NO is very stable 
in model aqueous media. The NO complex (MGD)2-Fe(II)-NO complex, if injected, is stable 
in tissues and organs as confirmed by L-band EPR measurements as reported elsewhere 
[Lai, et al. 1994, Mulsch, et al. 1999]. These authors confirmed the assignment as (MGD)2-
Fe(II)-NO from the hyperfine coupling J constant of this signal (see Figure 5). However, LPS 
complex accumulates in liver, brain, heart, kidney [Yoshimura, et al. 1996]. NOS inhibitor, 
N-monomethyl L-arginine (L-NMMA, 2 mM) confirmed that the NO complex is not bio-
reduced or biodegraded in vivo based on the EPR spectrum of (MGD)2-Fe(II)-NO complex. 
The stability of (MGD)2-Fe(II)-NO complex was at least 12 hours. In other report, the 
reduction/ decomposition of the NO complex occurred in the presence of 1 mM ascorbic 
acid or glutathione inhibitor with a half-life of 40 and 48 min, respectively [Perrier, et al. 
2009]. All these evidences indicate the NO complex as stable, non-biodegradable or 
decomposed form of (MGD)2-Fe(II)-NO complex as strong proton relaxation enhancer with 
paramagnetic properties [Perrier, et al. 2009, Fujii, et al. 2007]. All these evidences also 
indicated the NO complex as stable, non-biodegradable or decomposed form of (MGD)2-









DNIC (240 µmol/L) 931 ±3 7   
DNIC-cysteine  0.23 ± 0.06 0.33 ± 0.03 
DNIC-GSH(230 µM) 850 ± 24 0.11 ± 0.02 0.19 ± 0.03 
DNIC-BSA(160 µM) 247 ± 13 0.71 ± 0.09 1.37 ± 0.30 
MNIC-MGD   0.97 ± 0.09 1.37 ± 0.03 
MGD 55.5 52.4   
(MGD)2-Fe(II)-NO     T1 13.3* 13.9**   
(100 nmol/g)              T2 8.3* 8.7**   
(MGD)2-Fe(II) 24.9 25   
 
# The strong magnetic moment of the unpaired electron promotes both spin lattice and spin-spin 
relaxation of the surrounding water protons, resulting with decrease in their spin-lattice (T1) and spin-
spin (T2) relaxation times or enhancement in signal intensity on T1 or T2 weighted MR images. 
Relaxation constants of (MGD)2-Fe(II)-NO, (MGD)2-Fe(II) at 500 MHz* and 300 MHz** is shown 
indicating that relaxivity is not magnetic field dependent over this range.  
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In other study, NO complex was prepared from NO gas and (MGD)2-Fe(II) in glass 
capillaries. The strong magnetic moment of the unpaired electrons promote both spin lattice 
and spin-spin relaxation of the surrounding water protons and show a decrease in their 
spin-lattice (T1) and spin-spin (T2) relaxation constants or show enhanced signal intensity in 
T1 or T2 weighted MR images as shown in Table 2 and Figure 5 [Hortelano, et al. 2005]. 
Major points were:  
 The relaxation constants of (MGD)2-Fe(II)-NO in aqueous media were characteristic and 
complex concentration dependent;  
 T1 and T2 relaxation constants of liver were measured 1.17(1/mM * sec) and 1.32 
(1/mM * sec) respectively at 500 MHz at increasing concentration of NO;  
 T1 relaxation constant of (MGD)2-Fe(II), was reported 0.044 (1/mM * sec) at both 20 
MHz and 85 MHz magnetic fields. The T1 relaxation constant was field independent;  
 Distinct increase in relaxivity after complexing NO with (MGD)2-Fe(II). These unique 
properties of complex suggested its feasibility to visualize the regional distribution in 
tissue in vivo where the NO was trapped.  
In previous study, (MGD)2-Fe(II)-NO and LPS complexes were used as in vivo MR contrast 
agents [Fujii, et al. 2007]. First, intraperitoneal injection of 2 ml of 9.1 mM (MGD)2-Fe(II)-NO 
complex (150 nmol/g tissue) showed relative difference on T1-weighted MR images of rat 
liver site before and after injection of NO complex as shown in Figure 5.  
 The images indicated the NO complex very effective ‘‘intrinsic contrast agent,’’ to 
enhance the contrast in several other organs.  
The Second, LPS injected animals after 6 hours of (MGD)2-Fe(II) injection, showed 
subsequent MRI detection and reproducible visualization of NO generated in liver of 
animals as shown in Figure 5 and Fig. 6a (indicated by the arrow) as plots against time with 
the intensity of the reference water sample. Figure 6b showed that the image intensity in the 
liver increased with the NO generation, without any intensity change in reference sample in 
the presence of the specific NOS inhibitor N-monomethyl L-arginine (L-NMMA).  
Interestingly, other face of (MGD)2-Fe(II)-NO complex is ‘spin trap’. Spin traps are chemical 
compounds used to detect unstable free radicals such as hydroxyl (*OH) and superoxide (O2*-) 
in biological systems. Spin trapping compounds (spin traps) selectively react with NO and 
trap the nitric oxide. The spin-trap stock (MGD)2-Fe(II) complex solution (mixture of 
deoxygenated saline MGD (100 mM) and FeSO4 (20 mM) solutions in nitrogen) makes 
(MGD)2-Fe(II)-NO complex by mixing (MGD)2-Fe(II) with either pure NO gas or S-nitroso-N-
acetyl DL-penicillamine (SNAP). The pure NO gas is prepared by passing NO gas through a 
KOH solution. Major concern was the coordination of NO to the Fe complex altered the 
solubility of N0-Fe(II)(MGD)2 < 1 mM. The in vivo half life of N0-Fe(II)(MGD)2 was 41 minutes 
and only 40% trapped NO was estimated by detection of Fe(II)(MGD)2 induced inhibited NOS 
and decrease in NO formation and perfusion in the tissue [Fichtlscherer, et al. 2000]. 
 2NO + Fe(III)(MGD)2          H2O (*OH)_______ NO-Fe(II)(MGD)2 + NO2-  
(1)
 
NO + Fe(III)(MGD)2 ____Reducing Equivalent____ NO-Fe(II)(MGD)2 (40%) 
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MR contrast due to trapped NO can be expressed in Eq 2, 3: 
 1/T1[NO-Fe(II)(MGD)2] = 1/T1(observed) – 1/T* = r1i[NO-Fe(II)(MGD)2] × concentration (2) 
 1/Tobs = 1/T*+ r1i[NO-Fe(II)(MGD)2]; i = 1, 2... (3) 
where T1(observed) is long longitudinal relaxation time constant and T1* is short longitudinal 
relaxation time constant in absence of [NO-Fe(II)(MGD)2], r1i is longitudinal relaxivity 
dpends on I = 1, 2, 3 the number of carbons in branch of MGD chain, [NO-Fe(II)(MGD)2], 
concentration and interaction with NO specific bioactive receptor, enzyme, antibody, 






Fig. 5. Imaging of preformed (MGD)2-Fe(II)-NO complex. Transverse T1-weighted MR 
images in the axial plane of the liver of Wistar rats. Two ml of 9.5 mM (MGD)2-Fe(II)-NO 
complex was injected i.p. in the lower abdomen of 250 g rats (n = 3). a: Control, before 
injection; b: 60 min after injection of (MGD)2-Fe(II)-NO complex. A sketch at bottom shows 
the interaction of No with heme as basis of MRI signal. Reproduced with permission for 
reference Fujii, et al. 2007. 
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Fig. 6. Imaging of NO in six phantoms and LPS-treated rats. a: Transverse T1-weighted MR 
images focussed on a selected region of the liver in LPS-doped rats. The MR images were 
measured at the times indicated. Six hours after LPS injection, the NO spin-trap [3 ml of 
(MGD)2-Fe(II), MGD: 100 mM, Fe: 20 mM] was administered i.p. b: Plot of MR image intensity 
with time. Signal intensities were averaged over the selected region indicated by the arrow in a 
(7*7 mm2) for three different animals (filled symbols), normalized to intensity of a reference 
(water in a tube placed next to the animal, open symbols). At zero time, the spin-trap, (MGD)2-
Fe(II), was added. c: Comparison of the signal intensity in a selected slice region of the liver in 
the presence and absence of the NOS inhibitor, L-NMMA. The image intensity in the liver was 
first normalized to the external standard noted above. The averaged intensity in the selected 
regions (7 x 7 mm2) was averaged (n = 3). L-NMMA (50 mg/kg in saline) was injected i.p. 3 h 
after LPS injection (Reproduced from reference Fujii et al. 2007).  
2.4 MRI measurement protocol design 
We developed a MRI protocol to investigate the regional distribution of (MGD)2-Fe(II)-NO 
in various organs. For whole animal imaging, protocols for relaxivity of (MGD)2-Fe(II)-NO 
were designed on a Bruker 500 MHz, to achieve millimolar relaxivity. For the animal 
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experiments, anesthesia was administered as sodium pentobarbital (30 mg/kg, i.p.) and 
ketamine (20 mg/kg, intra-muscular injection) before injection of contrast agent in animals. 
For imaging, animals were anesthetized by intubating with 14 gauge, 2 inch intravenous 
catheter (Abbocath Lab, IL) on nose with 30% oxygen/70% nitrogen mixture containing 5% 
isoflurane/air mixture to continuous supply through nose during MRI session. Animals 
were kept in vertical direction to the side of MRI gantry and 30 mm diameter RF insert 
covering kidneys in the center of magnet. During six hours after administration of LPS to 
Wistar rats (150–200 g) they were injected intraparitoneally with 3 ml of (MGD)2-Fe(II) 
[MGD:100 mM, Fe:20 mM] at different intervals. MR images of the anesthetized rats (n = 5) 
were obtained after 1 hr spin trap injection with a Bruker Biospin 500 MHz scanner 
(PARAVISION 3.2). 
Different imaging techniques are available in our lab on 500 MHz and 900 MHz scanners. In 
vivo NO induction was carried out according to previously reported methods with slight 
modifications [Lai, et al. 1994, Yoshimura, et al. 1996, Green, et al. 1998]. 
 Axial T2-weighted spin echo sequence with fat suppression (TR 2000 ms, TE 100 ms, 
flip angle 30; EC 1/1 15.6 kHz) was used for more detailed T2-weighted information in 
detecting solid tissues. 
 Axial T1-weighted images were acquired at TR/TE/flip angle = 750 ms/ 4.18 ms/25º, 
FOV/matrix size/spatial resolution = 2.6 x 1.4 cm2/ 256 x 256 ×75 μm, and the 
inversion time (TI approximately 250 ms) set to null the normal the background tissue.  
 Gradient echo sequence in-phase and opposed-phase(TR 180 ms, TE 2.3 ms/4.5 ms, flip 
angle 30 were done as a dual echo sequence to show renal lesions hypointense and 
parenchyma isointense with hyperintense protein rich cyst. Opposed phased T1-
weighted gradient echo sequences were sensitive to fat. 
 Axial T1-weighted gradient echo sequence for dynamic perfusion/ diffusion weighted 
imaging (TR 130 ms, TE 1.0 ms, flip angle 30) was done after 30 ml intravenous 
gadolinium contrast injection for acquiring pre-contrast and post-contrast images in 
arterial phase to distinguish perfusion in the tissues. Parameters for T1-weighted spin-
echo images were TR 1500 msec, TE 10 msec, 2 NEX, 1-mm slice thickness, 0.5-mm slice 
gap, field of view 12 x 3 x 12 cm3, and matrix, 256 x 256.  
The original bird-cage coil with 2.6 cm diameter Rf insert was used for MR imaging. We 
established in lab MR image analysis by shareware software NIH Image J, a PC version 
supplied by Scion Corporation. The analysis of averaged image intensities from selected 
regions of interest 15 x 3 x 15, and matrix , 256 x 256 served as best for measurement of 
signal enhancement. An external reference (saline solution in a sealed test tube) placed near 
the animal serves to normalize intensities from both control and test groups. Percentage 
enhancements can be calculated from the normalized data [35]. Functional dependence of 
the MR imaging signal intensity S on the intrinsic properties (proton spin density N(H), T1, 
T2) has been derived based on the assumption of a monoexponential dependence on T1 and 
T2 with a spin-echo sequence: S(TE,TR) = N(H)exp(-TE/T2) [1 -exp[-(TR/ TE)/T1]]. The 
term on the right reflects the T1 dependence, and the exponential expression on the left 
reflects the T2 effects. TE << T2 generates a T1-weighted. T1 image is obtained by means of 
least-squares fitting (Marquardt-Levenberg algorithm) of the mean intensity values versus 
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TR. T2 weighted image is obtained by TR >> T2. Mean intensity values are fitted versus the 
TE (Marquardt Levenberg algorithm).  
T1 weitghted MR contrast due to trapped NO as NO-Fe(II)X spin trap in tissue can be 
expressed in Eq 4, 5: 
 1/T1[NO-Fe(II)X] = 1/T1(observed) – 1/T* = r1i[NO-Fe(II)X] × concentration (4) 
 1/Tobs = 1/T*+ r1i[NO-Fe(II)X]; i = 1, 2... (5) 
where T1(observed) is long longitudinal relaxation time constant and T1* is short longitudinal 
relaxation time constant in absence of [NO-Fe(II)X],  
r1i is longitudinal relaxivity dpends on i= 1, 2, 3 the number of carbons in branch of X 
contrast agent, its concentration and interaction with NO specific bioactive receptor, 
enzyme, antibody, hormone molecules in tissue.  
2.5 Approaches to NO evaluation by Magnetic Resonance Imaging (MRI) techniques  
Two major developments reported in context with NO. First, a search of NO specific stable 
multimodal MR/EPR sensitive spin trap complex; second, calibrating imaging 
characteristics of spin trap complex on NMR/MRI/PEDRI techniques. NO is perfused in 
gaseous phase or remains in ionic phase by redox state in the tissues. Both forms of NO are 
captured or trapped by Fe(II)-(DTC)2 complexes and show MRI signal change due to 
reactive nitrosylation (reaction of intracellular NO with Fe(II)(DTC)2 to form NO-
Fe(II)(DTC)2 complex) shown in Eq 6. Second-order rate constant of the reaction of NO with 
Fe(II)(ProDTC)2 was reported to be (1.1  0.3)×108 M-1 s-1[Caramia, et al. 1998].  
 Fe(II)(DTC)2Fe(II)(ProDTC)2 + NO  NO-Fe(II)(DTC)2 (6) 
Recently, attempts have been made to overcome the limitations of EPR-based imaging with 
low resolution and large sample size by employing new approaches of nuclear magnetic 
resonance (NMR) and magnetic resonance imaging (MRI) techniques. Several paramagnetic 
metal complexes have been widely used as contrast agents in magnetic resonance imaging 
(MRI) due to their ability to enhance the NMR relaxation of neighboring protons [von 
Bohlen, et al. 2003]. Paramagnetic NO-Fe-DTC complex has been utilized to visualize NO 
generated in living rats with septic shock [Fichtlscherer, et al. 2000, Fujii, et al. 1999]. 
Paramagnetic nitrosyl iron complex showed contrast properties to enhance the signal 
intensity of SNP-perfused rat liver in MRI [Fichtlscherer, et al. 2000, Fujii, et al. 1999]. Thus, 
a paramagnetic nitrosyl iron complex may be potentially useful as a microscopic localizer 
MRI contrast agent specific for NO accumulation in living organisms. Other proton-
electron-double-resonance-imaging (PEDRI) technique was based on the enhancement of 
proton NMR signal intensity in the presence of radicals through the Overhauser effect 
Mulsch et al. 1999,Foster, et al.1998]. Rat livers were exposed to SNP as an NO donor 
exhibited intense PEDRI images [Rast, et al. 2001, Jordan, et al.2004]. PEDRI imaging is a 
potential tool to study NO in large biological specimens. Still imaging application of MR 
and EPR spectroscopy using nitric oxide synthase inhibitors, oxygenation or perfusion are in 
infancy [von Bohlen, et al. 2003, Zhou, et al. 2009, Nagano, et al. 2002, Anbar, 2000] 
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Fig. 7. NO sensitive biomarker imaging contrast agents. Example of NO-Fe(II)(DTC)2 is cited 
to illustrate the signal change during changes in cerebral blood flow and possibility of 
functional MRI [Caramia, et al. 1998]. 
Two decades ago, NO activation-induced signal changes in functional MRI (fMRI) was 
observed [Di Salle, et al. 1997]. Hb–NO was found to produce marked stimulator dose and 
concentration-dependent NO sensitive fMRI signal intensity changes (increased after 
aqueous NO solution, nitrite, or dithionite and nitrite added to blood while it decreased on 
the addition of ascorbic acid) examined by T1-, T2-, and T2 -weighted MRI in venous 
erythrocytes with possibility of physiological MRI evaluation associated with NO change 
[Di Salle, et al. 1997]. Transient formation of two paramagnetic species (met Hb and NO-Hb) 
enhanced the signal intensity, while ascorbate reduced the signal intensity in fMRI 
experiment on healthy volunteers during standard tasks. Further, infusion of NO precursor, 
L-arginine increased the cerebral blood volume (measured by MRI) in nonischemic 
spontaneously hypertensive rats [Foster, et al. 1998]. In other study, administration of an 
NO donor, isosorbide dinitrate (ISDN) increased both tumor blood flow and partial oxygen 
pressure in mice implanted with liver tumor in the thigh [Jordan, et al. 2000]. These findings 
indicate blood flow-independent change in MRI signal produced by different additives or 
stimulators. These observations open a new perspective on the monitoring of NO and the in 
vivo speculation of NO effects to test new drugs by using magnetic resonance techniques. 
Fuji et al. 1999 first time reported in vivo MRI of NO using Fe(MGD)2 as NO–Fe(MGD)2 spin-
trapping technique in a septic shock rat model [Fujii, et al. 1999]. (Fig. 6A). The reduced 
signal after administration of an iNOS inhibitor confirmed the MRI visibility of NO–
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Fe(MGD)2 complex especially in inflammation which has high levels of NO. Now many 
MRI visible nitrosyl-iron complexes are known for MRI mapping of NO using a 
conventional 1.5 T MR scanner. The principle is that after exposure to NO in tissues 
Fe(MGD)2 imaging agents form nitrosyl-iron complexes, which shorten the T1 and T2 
relaxation time in a concentration-dependent manner [Hong, et al. 2009]. Mainly, four major 
techniques are reported in quest of developing new NO sensitive MRI contrast agents. First, 
unpaired electrons of the nitrosyl–iron complexes can enter into dynamic nuclear 
polarization with water protons, a technique called proton-electron-double-resonance 
imaging (PEDRI). Second, superparamagnetic iron oxide (SPIO) or ferumoxides dephase T2-
weighted MRI signal dependent on SPIO: NO donor ratios indicating inverse relation of 
contrast enhancement by SPIO with increasing levels of NO in tissue. The MRI signal 
change was due to reduction of ferric to ferrous iron with result of decrease in paramagnetic 
relaxation of water protons [Kojima, et al.2001]. Third, technical development emerged as 
irreversible paramagnetic chemical exchange saturation transfer (PARACEST) based MRI 
contrast agents in imaging [Liu, et al. 2007, Zhang, et al. 2003, Wu, et al. 2008]. A 
PARACEST MRI agent, Yb(III)-(1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid)-
orthoaminoanilide (Yb-DO3A-OAA), was developed for NO detection (Fig. 6B) [9]. Fourth, 
NO and O2 combine by irreversible covalent bond that causes a quick disappearance of the 
PARACEST effect captured in the MR images. PARACEST MRI is fast data acquisition (in 
few minutes) vs SPIO based imaging is slow (in few hours). PARACEST effect has poor 
sensitivity (only detects millimolar concentrations of NO). 
2.6 Approach of real-time NO synthase inhibition as blood oxygenation dependent 
MRI signal  
Nitric oxide synthase inhibition (NOSi) in humans by blood oxygenation level-dependent 
(BOLD) MRI as reduced response to NOSi was reported using BOLD MRI to compare 
changes in R2* to direct measures of renal medullary oxygen levels and blood flow using N-
nitro-L-arginine methyl ester invasive probes (OxyLite/OxyFlo) to examine for the first time 
the effect of NOSi on intrarenal oxygenation in humans [Li, et al. 2009, Di Salle, et al. 1997]. 
Authors showed that NOSi decreased medullary pO2 and blood flow in a dose-dependent 
manner, and BOLD MRI showed an increase in medullary R2* consistent with the invasive 
pO2 measurements.  
Other alternate approach of positron emission tomography (PET) was proposed in recent 
study using nitric oxide imaging probe prepared from [18F] 6-(2-fluoropropyl)-4-methyl-
pyridin-2-amine by substitution at position-6 of substituted 2-amino-4-methylpyridine with 
favorable properties as a PET tracer to image iNOS activation/expression with PET of 
animal lungs [Zhou, et al. 2009].  
3. Major developments in NO bioimaging probes 
3.1 Magnetic resonance relaxation enhancement mechanism 
In 1999, the first in vivo MRI of NO was reported using the spintrapping technique in a 
septic shock rat model [Fujii, et al. 1999]. NO was trapped by Fe(MGD)2 in vivo, which can 
be visualized by MRI. The NO–Fe(MGD)2 complex displayed significantly enhanced 
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contrast in the vascular structure, such as the hepatic vein and inferior vena cava, which can 
be reduced after administration of an iNOS inhibitor.Initially, NO mapping was reported by 
whole body EPR imaging at poor resolution [Claudette, et al. 2005,Yoshimura, et al. 1996]. 
Recently, MRI strategies combined with in vivo spin-trapping map ‘‘NO distributions’’ 
within tissues and organs showed much higher spatial resolution using (MGD)2-Fe(II)-NO 
as a NMR contrast agent in vivo [Fichtlscherer, et al. 2000]. The MR images also provided 
follow-up of NO generation kinetics at different sites within the organ at much higher 
spatial resolution than with EPR [Claudette, et al. 2005,Yoshimura, et al. 1996]. NO makes 
stable complex such as (MGD)2-Fe(II)-NO. In vivo, hemoglobin is normally the natural NO 
spin-trap such that NO tends to bind with hemoglobin or oxidize the hemoglobin, followed 
by conversion to nitrosyl-hemoglobin or methemoglobin, both of these complexes are 
paramagnetic. Authors believe that during brain stimulation, NO is generated in some 
regions and it is quite possible that (paramagnetic) nitrosyl-hemoglobin and methemoglobin 
are formed in these active regions in brain. The MRI signal intensity enhancement in these 
regions results from changes in blood flow rich with these complexes. However, for blood 
flow–independent effects in MRI, the paramagnetic relaxation from spin-trapped NO might 
provide a new fMRI contribution in future. To our knowledge, there have been no reports 
successfully imaging or detecting free radicals such as NO in vivo by NMR or fMRI. 
Further, both short lifetime and rapid diffusion of NO in time preclude any effective 
relaxation enhancement mechanisms. NMR spin trapping serves to overcome these 
problems such as NO short lifetime and its fast diffusion in tissues to some extent. In other 
classic study on rats, spin relaxation constants of dinitrosyl-iron bound albumin or GSH and 
mononitrosyl-iron dithiocarbamate MGD complexes showed concentration dependence by 
MRI technique [Fujii, et al.1999]. 
3.2 Emission enhancement mechanism 
Present state of art in NO detection was developed over last 2 decades using fluorescein 
cheletropic compounds visualized by emission enhancement and photoinduced electron 
transfer mechanisms. Fluorescence properties of fluorescein derivatives are controlled by 
the photoinduced electron transfer (PET) process from the benzoic acid moiety to the 
fluorophore, the xanthene ring. PET is a widely accepted mechanism for fluorescence 
quenching in which electron transfer from the PET donor to the excited fluorophore 
diminishes the fluorescence of the fluorophore. A brief survey of these compounds and their 
fluorescence mechanisms will catch the attention of readers with the newer developments of 
NO detection in tissues. EPR (also known as electron spin resonance or ESR) explores the 
magnetic moment associated with the unpaired electron(s) in free radicals and paramagnetic 
metal ions [Mader, 1998, Swartz, 2007]. It has been applied for the detection of free radicals 
and paramagnetic metal ions in various biological conditions [Berliner, et al. 2004]. When an 
unpaired electron in a paramagnetic molecule is subjected to an external magnetic field, the 
energy level of the electron splits into two quantum states with different energy levels. 
Typically, the magnetic field is scanned with a fixed microwave frequency of approximately 
9.5 GHz (usually called the X-band). Specimens less than about 100 μL are measurable in an 
Xband spectrometer. However, larger biological samples (e.g., tissues, organs, and live 
animals) cannot be measured with a conventional X-band spectrometer due to the high 
dielectric loss of water at such frequencies and the small size of the EPR cavity resonator. 
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EPR spectroscopy at lower frequencies, the L-band (0.4–1.6 GHz) or S-band(1.6–4 GHz), can 
be used for in vivo EPR imaging. EPR imaging is generally considered to be the most 
effective technique for noninvasive observation of the spatial distribution of free radicals 
[Kleschyov, et al. 2007]. Direct EPR detection of endogenous free radicals in biological 
samples requires that the radical of interest is present at a concentration higher than the 
practical detection limit (0.1–0.01 μM) and has a relatively long lifetime. Although such 
requirement can be met at cryogenic temperature, in vivo detection is almost impossible 
since most radicals do not have a sufficiently long lifetime. Therefore, spin-trapping 
techniques have been developed in which the spin traps can react with unstable free radicals 
to form a relatively stable adduct [Berliner, et al. 2004, Davie, et al. 2004]. The formation of 
the long lived adduct results in accumulation of steady-state free radicals which can be 
detected readily by EPR spectroscopy.  
In principle, the fluorescence properties of fluorescein derivatives are controlled by the 
photoinduced electron transfer (PET) process from the benzoic acid moiety to the 
fluorophore, the xanthene ring. PET is a widely accepted alternate mechanism for 
fluorescence quenching in which electron transfer from the PET donor to the excited 
fluorophore diminishes the fluorescence of the fluorophore. The fluorescein structure has 
two parts confirmed by X-ray analysis, i.e., the benzoic acid moiety as the PET donor and 
the xanthene ring shown as the fluorophore in previous study [Liu, et al. 2007]. The study 
showed that only small alterations in absorbance were observed among fluorescein and its 
derivatives. The dihedral angle () between the benzoic acid moiety and the xanthene ring 
was almost 90o. It also suggested that there is little ground-state interaction measured by 
HOMO energy levels between these two parts.  
The relationship of HOMO energy levels and () angle of fluorescent compounds predict the 
fluorescence mechanism of benzoic acid moiety in the compounds. If the HOMO energy 
level of the benzoic acid moiety is high enough for electron transfer to the excited xanthene 
ring, the  value will be small. In other words, fluorescein derivatives with a high  value 
must have benzoic moieties with low HOMO energy levels. The HOMO energy levels of 3-
aminobenzoic acid, 3-benzamidobenzoic acid, 3,4-diaminobenzenecarboxylic acid (DAB-
COOH), and benzotriazole-5-carboxylic acid (BT-COOH), which are the benzoic moieties of 
aminofluorescein, benzamidofluorescein, DAF-2, and DAF-2T, respectively were estimated 
by semi-empirical (PM3) calculations. DAB-COOH and aminobenzoic acid, which are the 
benzoic acid moieties of weakly fluorescent fluorescein derivatives, have higher HOMO 
levels than BT-COOH and amidobenzoic acid. These results were consistent with the PET 
mechanism. 
Further, to confirm this mechanism 9-[2-(3-carboxy)-naphthyl]-6-hydroxy-3H-xanthen-3-one 
(NX) and 9-[2-(3-carboxy)anthryl]-6-hydroxy-3H-xanthen-3-one (AX) were synthesized 
[Nagano, et al. 2002]. It is well-known that expanding the size of aromatic conjugates makes 
their HOMO levels higher, similar with by introducing electron-donating substituents. 
Thus, naphthoic acid and anthracene-2-carboxylic acid would have higher HOMO levels 
than benzoic acid, and therefore, the fluorescence properties of NX and AX would differ 
from those of fluorescein.. The absorbance maximum (Exmax) and emission maximum 
(Emmax) of NX and AX were closer and not much altered among these fluorescein 
derivatives. However, the  values were greatly altered; NX is highly fluorescent, whereas 
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AX is almost nonfluorescent [Nagano, et al. 2002]. Thus, a small change in the size of 
conjugated aromatics, namely, from naphthalene to anthracene, causes a great alteration of 
the fluorescence properties. Authors compared the HOMO levels of the benzoic acid 
moieties with xanthine ring and naphthoic acid. Napthoic acid moiety is present in highly 
fluorescent fluorescein and NX. The HOMO levels of benzoic acid moiety were lower than 
that of the xanthene ring, while the HOMO level of anthracenecarboxylic acid moiety in 
fluorescent AX, was higher than that of the xanthene. These results were consistent with the 
idea that a PET process controls the fluorescence properties of fluorescein derivatives and 
that these properties can be predicted from the HOMO level of the benzoic acid moiety, 
with a threshold at around -8.9 eV. This in turn provides a basis for developing novel 
fluorescence probes with fluorescein-derived structure. Still much remains to justify the 
fluorescent probes in NO bioimaging. 
 
Fig. 8. Representative spin-trapping agents for EPR imaging of NO. 
Fe(MGD)2 or Fe(DETC)2 have also been tested for EPR imaging to map the spatial 
distribution of NO generation in the ischemic myocardium [Kuppusamy, et al. 1996]. 
Subsequently, Fe(MGD)2 was used in both EPR and MR imaging in rats with sepsis shock 
[Fujii, et al.1999]. It was reported that Fe(MGD)2 can reduce nitrite to NO at physiological 
pH, which may cause some detection Inaccuracy as shown in Figure 8, although the rate 
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constant is quite slow (1–5 M−2 s−1) [Tsuchiya, et al. 2000]. Fe(DETC)2 has been used for 
imaging vascular NO production in rabbits [Kleschyov, et al. 2000], animal brain injury 
[Ziaja, et al. 2007], vascular disease [Khoo, et al. 2004], and even in plants [Xu, et al. 2004, 
Vanin, et al. 2007]. Heme proteins, such as myoglobin, cytochrome c, and catalase, have 
been used as NO-trapping agents in various biological specimens[Kleschyov, et al. 2000]. 
Although the EPR signals of heme–NO species can be observed in tissues exposed to 
elevated levels of NO, it is almost impossible to discriminate between the individual 
nitrosylated heme proteins due to overlapping of the signal. Generally, the dominant heme–
NO EPR signal belongs to the major heme protein expressed in the tissue (e.g., myoglobin in 
the heart [Konorev, et al. 1996]). The most frequently used heme protein in EPR research is 
hemoglobin (Hb) [Kosaka, et al. 1994], which can interact with NO to generate several 
paramagnetic Hb–NO derivatives detectable by EPR spectroscopy [Picknova, et al. 2005]. 
Different preparations of deoxy-Hb have been used for NO trapping in isolated cells and 
organelles [Kozlov, et al. 1996]. 
3.3 NO imaging and fluorescent dyes 
Several fluorescence indicators for direct detection of NO have been generated, which might 
be useful for in vitro or in vivo NO-imaging. These substances interact with NO to form a 
fluorescent complex. Several fluorescent dyes have been developed, which can be used for 
NO bioimaging. However, several of these promising fluorescent dyes have been found not 
to be very specific such as 2′,7′-dichlorofluorescein (DCF) or to be cytotoxic such as 2,3-
diaminonaphthalene (DAN). Of specific mention, iron (II) N-(dithiocarboxyl) 
sarcosine(Fe(DTCS)2; Fig. 5) trapping agents within 1 h after injection of the spin trap 
generated stable signal which indicated that the formation of the steady-state free radical 
had reached equilibrium. The same trapping agent was also tested for NO imaging in 
lipopolysaccharide-treated mice [Quaresima, et al. 1996]. Subsequently, EPR measurements 
and EPR-CT (CT denotes computed tomography) imaging with Fe(DTCS)2 were carried out 
in live mice [Yokoyama, et al. 1997]. The use of Fe(DTCS)2 resulted in a clear EPR-CT image 
showing high intensity areas in the ventral regions, while other NO-bound iron complexes 
such as Nmethyl-D-glucamine dithiocarbamate (Fe (MGD)2; Fig. 5) or N,Ndiethyl-
dithiocarbamate (Fe(DETC)2) gave much lower signal-to-noise ratios. Several compounds 
such as 5,5-dimethyl-1-pyrroline N-oxide (DMPO; Fig. 5), ǂ-phenyl-N-tert-
butylnitrone(PBN), or 3,5-dibromo-4-nitrosobenzene sulfonate (DBNBS), NO cheletopic 
traps (NOCTs), aci anions of nitroalkanes, iron (II)–dithiocarbamate(DTC) complex 
and(DAFs) are fluorescein derivatives. DAFs themselves scarcely fluoresce while DAF-Ts 
are strong fluorescent compounds. However, the mechanisms accounting for the diminution 
of fluorescence in DAFs and fluorescence enhancement in DAF-Ts remain unclear.Other 
fluorescent Fe(DTCS)2 and Cobalt based dyes have been tested in some cell culture systems, 
but these substances have not been tested in in vivo or in vitro acute brain slice preparations 
or tissues [von Bohlen, et al. 2003, Zhou, et al. 2009]. Until now, several other fluorescent 
dyes have been promising candidates for the evaluation of the temporal and spatial aspects 
of NO generation and distribution even under microscopic observation, including 
diaminofluoresceins (DAFC), diaminorhodamines (DAR), diaminoanthraquinone (DAQ), 
fluorescent resonance energy transfer (FRET) and the “fluorescent nitric oxide cheletropic 
traps” as shown in Table 3 [von Bohlen, et al. 2003, Zhou, et al. 2009]. 
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In following section, we will summarize the progress to date on multimodality imaging of 
NO and NOS expression and address future research directions and obstacles for NO/NOS 
imaging using biosensors as outlined in Figure 9. For interested readers, basic methods of 
NO detection and imaging are given in Appendix in then end of this chapter. 
 Fluorescence imaging of NO:  
2,7-dichlorofluorescin was introduced for NO detection. When it is oxidized by NO, a 
fluorescent compound (dichlorofluorescein) is formed. Besides a relatively poor 
detection sensitivity (~ 10 μM of NO), 2,7-dichlorofluorescein also has very low 
specificity for NO. Later several iron (II) complexes, fluorescently labeled cytochrome c 
(a hemoprotein that binds NO selectively), cobalt complexes and fluorescent NO 
cheletropic traps (FNOCTs) were introduced. The iron(II) complex of quinoline pendant 
cyclam has fluorescence emission at 460 nm, which can be quenched effectively by NO 
from NO releasing agents. 2,2,6,6-tetramethylpiperidine-N-oxyl (TEMPO) labeled with 
acridine and Fe(II)-(N-(dithiocarboxy) sarcosine)2 complex (Fe(DTCS)2) (Fig.5), was 
developed. The addition of an NO-releasing reagent causes a decrease in the 
fluorescence signal due to the irreversible binding of NO to the Fe(II).  
 DAFCs are the most successful and extensively investigated agents for NO imaging. In 
vivo imaging of NO in whole living vertebrate with the DAF compounds was reported, 
where diaminofluorophore 4-amino-5-methylamino-2′-7′-difluorofluorescein diacetate 
(DAF-FM-DA) was used to detect NO production sites in the zebrafish Danio rerio. The 
specificity of the fluorescent signal was confirmed by a decrease in animals exposed to a 
NO scavenger or a NOS inhibitor, as well as an increase in the presence of a NO donor. 
Local changes in NO production in response to stressful conditions could also be 
imaged by this agent, suggesting that DAF-FM-DA can be used to monitor changes in 
NO production which may have future applications in drug screening and molecular 
pharmacology. Best example of NO imaging in vivo with the DAF compound in 
zebrafish is quite transparent. The major limitation of the DAF-2 compound is that it is 
not specific to NO because it can also react with dehydroascorbic acid (DHA) and 
ascorbic acid (AA) to generate new compounds that have fluorescence emission profiles 
similar to that of DAF-2T. 
 Similar to DAF and DAR, rhodamine fluorophore was developed and it was termed “the 
DAR”. To image NO in living cells, DARs should be membrane permeable. Therefore, an 
ethyl group was introduced into the carboxyl group of DAR-1 (4,5-diamino-N,N,N′,N′-
tetra ethyl rhodamine), anticipating that the ethyl ester would be hydrolyzed by cytosolic 
esterases after permeation through the cell membrane [Kojima et al. 2001]. 
 New class of DAQ compounds of DAFC family called diaminocyanines (DACs) were 
prepared with a tricarbocyanine as the NIR fluorophore and o-phenylenediamine as the 
NO sensitive fluorescence modulator. It was reported that these compounds can react 
faster with NO than the DAFs and the reaction efficiency was at least 50 times higher than 
that of DAF-2. Although it was demonstrated that NO can be imaged in isolated rat 
kidneys, in vivo imaging of NO using these compounds has not been reported. 
 A new class of difluoroboradiaza-s-indacene-based agents have been widely used in the 
detection of NO in cells or tissues [Huang, et al. 2002a]. One of these compounds, 
1,3,5,7-tetramethyl-8-(4′-aminophenyl-N-(2′′-amino)-phenzyl)-difluoroboradiaza-s-
indacene (TMAPABODIPY), was shown to have high photostability, high sensitivity 
(detection limit is 5 nMof NO), and no pH dependency over a wide pH range (see 
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Figure 9). Subsequently, a similar compound, 1,3,5,7-tetramethyl-2,6-dicarbethoxy-8-
(3′,4′diaminophenyldifluoroboradiaza-s-indacene (TMDCDABODIPY), was applied for 
real-time imaging of NO in cells [Huang, et al. 2002b]. 
 
 MGD DAF DAR DAQ 
Emission (color)  ~520 nm (green) ~515 nm(green) >580 nm(red) 460 nm(blue) 
Excitation  ~460 nm ~495 nm ~550 nm ~520 nm 
Reacts with ROS Generates No -- No 
Tested in 
neurotoxic tissues 
No Yes No Yes 
Neurotoxic  -- No -- No 
Table 3. Properties of fluorescent NO-indicators  
 In copper-based fluorescent compounds copper (II) is coordinated with certain 
fluorophores, the base-catalyzed reaction with NO leads to the reduction of the metal 
center and the intramolecular nitrosylation of a secondary amine. Based on this 
mechanism, a series of fluophore coordinated copper (II) complexes were designed for 
NO imaging [Lim, 2007]. Reduction of the Cu (II) core by NO to Cu(I) with nitrosation of 
the fluorescent ligand is accompanied by bright fluorescence emission. Any 
nitrogen/oxygen reactive species or ascorbic acid do not cause any significant 
fluorescence alteration in Cu(II)-based agents. Cu(II) complexes are quite successful in NO 
imaging in cell culture but they have not been tested in vivo likely due to the suboptimal 
emission wavelength, the potential toxicity, and the poor in vivo stability of the Cu(II) 
complex. Recently, several benzimidazole derivatives have been tested in vivo for NO 
imaging [Quyang, et al. 2008]. The fluorescent 5′-chloro-2-(2′-hydroxyphenyl)-1H-
naphtho[2,3-d]imidazol and 4-methoxy-2-(1H-naphtho [2,3-d]imidazol-2-yl)phenol can 
coordinate with Cu(II) to form a nonfluorescent coordination compound, which can 
detect NO production in inflammation with a turn-on fluorescence. NO production was 
imaged successfully in both activated murine macrophages and an acute severe hepatic 
injury (ASHI) mouse model. Although these agents represent the first successful attempt 
of in vivo fluorescence imaging of NO, the actual imaging was performed ex vivo on 
frozen tissue slices due to the suboptimal fluorescence emission wavelength as shown in 
Figure 10. Much further optimization of these Cu(II)-based agents will be needed in the 
future, in particular fluorescence emission in the NIR range and reduction of the toxicity. 
 Imaging NO/NOS with FRET: FRET agents react with NO covalently a irreversible 
sensors for NO. Further, some of the organic dyes can accumulate in subcellular 
membranes and emit fluorescence signals in an NO-independent manner which can 
cause significant background signal and interfere with the detection of NO. To 
overcome these limitations, a NO-selective sensor with the heme domain of soluble 
guanylate cyclase (sGC) was developed [Barker, et al. 1999]. The heme domain of the 
sGC was labeled with a fluorescent dye and domain changes in the fluorescence 
intensity of the dye based on the sGC heme domain's characteristic binding of NO. It 
was found that these sensors have fast, linear, and reversible responses to NO 
unaffected by other radical species. However, the detection limit is only about 10 μM of 
NO which makes less useful. 
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Fig. 9. Imaging NO with diamino-aromatic fluorescent compounds. (A) The general reaction 
that leads to NO detection by fluorescence with this class of agents.  
(B) Fluorescence image of live zebrafish larvae loaded with DAF-FM-DA. Blue arrow, heart; 
orange arrow, the cleithrum; purple arrow, the notochord; yellow arrow, the caudal fin.  
(C) Distribution of NO in B16F10 tumors grown in the cranial window in mouse. Left: 
microangiography using tetramethylrhodamine-dextran; middle: representative 
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microfluorography captured 1 h after the loading of DAF-2 in tumors; right: The animals 
were treated with NOS inhibitor. Color bar shows calibration of the fluorescence intensity 
with known concentrations of DAF- 2T. (D) Left: fluorescent image of endothelial cells with 
DAR-4M AM at 10 min after the stimulation. Right: an antagonist of the stimuli strongly 
abolished the fluorescence intensity. (E) Confocal laser fluorescence microscopy image of 
cells loaded with DAQ and stimulated to produce NO. Left: bright-field; middle: 488 nm 
excitation; right: 543 nm excitation. (F) Bright-field and fluorescence images of activated 
PC12 cells loaded with TMDCDABODIPY in the presence of arginine. Adapted from 
[Huang, et al. 2007a, 2007b]. 
 
Fig. 10. Copper-based fluorescence imaging of NO. (A) CuFL detection of NO produced by 
iNOS in macrophage cells after different time of incubation. Top: fluorescence images; 
Bottom, bright-field images. (B) Fluorescence images of excised liver slices harvested from 
live animals after intravenous injection MNIP-Cu. Left: normal mouse liver; center: ASHI 
liver; right: Kupffer cell-depleted ASHI liver. Adapted from reference [Quyang, et al. 2008]. 
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Subsequently, a genetically encoded fluorescent indicator for NO was developed based on 
FRET, which can reversibly detects NO with high sensitivity (detection limit of 0.1 nM) and 
visualizes the nanomolar dynamics of NO in single living cells on NO induction [Jares-
Erijman, et al. 2003]. However, this approach requires genetic encoding and it generates the 
biologically active molecule cyclic guanosine monophosphate (cGMP), which can induce other 
cellular responses. The cGMP molecules can bind to both the NO-associated and the No free 
probe, resulting in an increase in fluorescence. Therefore, the signal generated is a reflection of 
the intracellular concentration of cGMP rather than that of NO per se. Recently, the use of 
confocal based spectral imaging with NO-sensitive FRET reporters enabled NO imaging in the 
vasculature of intact, isolated perfused mouse lung[St Croix, et al. 2008]. Using calibration 
spectra, it is possible to unambiguously separate the cross-talk between overlapping donor 
and acceptor emissions. Overall, FRET is a very powerful technique in cell-based experiments 
but with only very limited potential applications in animal studies as shown in Figure 11. 
3.4 NO bioimaging by bioluminescence and chemiluminescence imaging  
The major application of chemiluminescence in NO imaging/ detection lies in gas phase or 
liquid phase measurements[Taha, et al. 2003]. The major chemiluminescence activators for NO 
imaging include ozone, luminol, and lucigenin. Gas phase chemiluminescence detection of NO 
is generally based on the reaction of NO with ozone to produce excited-state nitrogen dioxide. 
When it returns to the normal state, light is emitted at about 600 nm wavelength.  Such gas 
phase detection has been widely used for measuring NO in exhaled breath to detect 
inflammatory diseases of the lung. Gas phase chemiluminescence detection has very high 
specificity, as well as extreme sensitivity, which can reach parts per billion (ppb). However, 
drawbacks include inconvenient instrumentation, high cost, and timeconsuming detection 
procedure. To overcome these problems, an optimized chemiluminescence detection system 
for NO was developed. For liquid phase chemiluminescence imaging of NO, currently the 
luminol/H2O2 detection system is the most useful [Robinson, et al. 1999]. Alkaline luminol can 
react with NO to generate luminescence. The presence of H2O2 as an activator can enhance the 
sensitivity by about 20-fold. Two approaches have been used for luminol/H2O2-based imaging 
of NO. In the first approach, the sample is directly added to the luminol/H2O2 mixture. This 
strategy can detect very low levels of NO, which is quite useful for visualizing the production 
of NO from cells or organs, but it lacks NO specificity since luminol can react with many free 
radical species. In the second strategy, a selective dialysis membrane is placed between the 
sample and the luminol/H2O2 mixture. This procedure can offer better specificity yet it suffers 
from poor sensitivity, slow response time, and undesirable NO detection limit (μM level). 
Besides ozone and luminol, lucigenin is can also be used for NO detection. Lucigenin has been 
widely used as a chemiluminescent substrate to monitor vascular superoxide formation. In 
particular, lucigenin at a concentration of 5 μM could be used as an indirect probe to estimate 
basal vascular NO release. Generally, chemiluminescence is a very sensitive method for NO 
imaging/detection. However, the disadvantages such as low specificity and time-consuming 
procedure make chemiluminescence not very useful as an independent technique for NO 
imaging/detection. 
Several other imaging techniques have been investigated for NO detection. As an important 
component of molecular imaging, ultrasound is not inherently suitable for direct NO 
imaging, although it can be used for evaluating the endothelial function or vasodilation 
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caused by NO [Heiss, et al. 2008]. It is worth noting that ultrasound at different frequencies 
can stimulate NO production in different contexts such as in endothelial cells, osteoblasts, 
and vascular dilation. A few other techniques such as time-resolved photoion and 
photoelectron imaging, Hb spectral alteration imaging, laser induced fluorescence detection 
(LIF), and calcium amplification imaging have also been studied for NO detection. In 
particular, LIF imaging was able to detect the NO release in a single cell, which makes it a 
very powerful tool for studying the kinetics of NO release by neuronal cells during 
neurotransmission. PET imaging of anesthetized dogs with inhaled radiolabeled 13NO has 
been performed to study the in vivo kinetics of NO [McCarthy, et al. 1996]. In future, 
molecular imaging may provide more accurate information on NO in intact living systems. 
EPR-CT [Yokoyama, et al. 1997], EPR-MRI [Berliner, et al. 2004], and EPR-
chemiluminescence imaging [Nagano, 2002] have all been attempted and much further 
research/optimization will be needed before any potential clinical investigation can be in 
place. 
3.5 Multimodal bioimaging of NOS gene expression 
Initially NOS was considered a sole enzyme to produce NO. Nitric oxide synthase (NOS) is 
also under extensive investigation [Crowell et al. 2003]. NO is biosynthesized as three 
distinct mammalian NOS isoforms shown in section 1. Neuronal NOS (nNOS or NOS I) and 
endothelial NOS (eNOS or NOS III) are constitutively expressed in neuronal and endothelial 
cells, respectively and both are referred to as cNOS. Inducible NOS (iNOS or NOS II) is 
expressed in cells involved in inflammation, such as macrophages and microglias when 
stimulated by cytokines and/or endotoxins. Although cNOS and iNOS do not have a 
significant difference in activity (both function through NO), cNOS expression can be 
stimulated by Ca2+ whereas iNOS activity is Ca2+-independent. Generally, the NO levels 
produced by cNOS in stimulated endothelial and neuronal cells are much lower (in 
nanomolar [nM] range) than those generated by iNOS in macrophages (micromolar [μM] 
range). Aside from NOS synthesis, recent studies have pointed out that nitrite reduction can 
also serve as a possible source of biologically relevant NO [Gladwin, et al. 2005]. Excessive 
production of NO is believed to be responsible for various pathophysiologies, while very 
low levels of NO are needed to maintain normal physiological conditions. Since the 
production of NO is closely associated with the expression of NOS, blocking NOS 
expression is a more convenient approach to inhibit the function of NO than intervention 
through NO itself.  
Molecular imaging refers to the characterization of NO/NOS and measurement of biological 
processes at the molecular level [Massoud, et al. 2003]. It takes advantage of traditional 
diagnostic imaging techniques and introduces molecular probes to measure the expression 
of indicative molecular markers at different stages of diseases. Molecular imaging 
modalities include molecular magnetic resonance imaging (MRI), magnetic resonance 
spectroscopy (MRS), optical imaging, targeted ultrasound, single photon emission 
computed tomography (SPECT), and positron emission tomography (PET). Many hybrid 
systems that combine two or more of these modalities are already commercially available 
and certain others are under active development. Molecular imaging can give whole body 
readout in an intact system at the cost of less workload, inexpansive drug development trial, 
and provide more statistically relevant results since longitudinal studies can be performed 
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in the same subjects [Cai, et al. 2008a, 2008b]. In the clinical setting, molecular imaging can 
significantly aid in early lesion detection, patient stratification, and treatment monitoring, 
which can allow for much earlier diagnosis, earlier treatment, better prognosis, and 
individualized patient management. To date, the multimodal imaging modalities for 
visualization of NO include optical imaging (fluorescence and chemiluminescence), electron 
paramagnetic resonance (EPR) imaging, and MRI. Meanwhile, NOS has been mainly 
investigated using optical and PET imaging. In following section, we describe recently 
developed multimodal techniques in their infancy. 
3.5.1 Optical imaging of NOS expression 
Imaging enzyme expression and function is quite challenging. Compared to the vast 
number of literature reports on NO imaging, much less effort has been directed toward NOS 
imaging. Briefly, the major modalities for NOS imaging include optical imaging, PET, and 
some other techniques such as electron microscopy. Historically, the study of NOS 
physiology was constrained by the lack of suitable probes to detect NOS in living cells or 
animals. In one pioneering study, a fluorescent iNOS inhibitor, pyrimidine imidazole FITC 
(PIF), was developed and investigated for microscopy of iNOS in living cells [Panda, et 
al.2005]. It is an isoform-selective molecule with high affinity to iNOS and the binding is 
essentially irreversible, which allowed for iNOS imaging in many cell types as well as 
freshly obtained human lung epithelium. This study indicated that fluorescent probes (e.g., 
PIF) can be valuable for studying iNOS cell biology and understanding the pathophysiology 
of diseases that involve dysfunctional iNOS expression. In another report, 
immunofluorescence staining was performed to evaluate nNOS expression on left inferior 
alveolar nerve (IAN) injury in ferrets [Davies, et al. 2004]. A possible translocation of nNOS 
protein from the cell body to the site of nerve injury was proposed. Lastly, some 
ruthenium(II) and rhenium(I)-diimine wires were reported to be capable of binding to iNOS 
in vitro to generate NIR fluorescence (710 nm emission), which may potentially be useful as 
a fluorescent imaging probe for iNOS [Dunn, et al. 2005]. The inflammatory modulating 
effects of iNOS on laser therapy were studied using bioluminescence imaging (BLI) 
[Moriyama, et al. 2005]. In this study, the efficiency of different wavelengths laser therapy at 
different wavelengths in modulating iNOS expression was determined using transgenic 
animals with a luciferase gene driven by the iNOS gene. On induction of inflammation 
followed by laser treatment, imaging of iNOS expression was performed at various times by 
measuring the bioluminescence signal. When compared with the nonirradiated animals, a 
significant increase in the bioluminescence signal was observed after laser irradiation which 
demonstrated that iNOS expression can be detected by noninvasive BLI. Comparing the two 
strategies for NOS imaging with optical techniques, many fluorescently labeled NOS 
inhibitors have charges which makes them not cell membrane permeable. NOS-controlled 
luciferase expression appears to be a preferable choice, yet much further optimization will 
be needed in future studies. Generally speaking, the limited penetration of light in tissue 
renders optical imaging only suitable for a limited number of scenarios (e.g., superficial 
regions-of-interest and endoscopy-accessible tissues). Another drawback of optical imaging 
is that it cannot give accurate quantitative analysis of the imaging result. Combination of 
quantum dot optical and radionuclide-based imaging techniques (e.g., PET) may 
significantly help in this aspect [Cai, et al.2007a, 2007b]. 
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3.5.2 PET imaging of NOS expression 
Small animal PET scanners have very good spatial resolution (1 mm) and they are also 
becoming increasingly widely available.  PET does not have a tissue penetration issue, it 
is highly quantitative, and it can be used for both diagnosis and treatment monitoring. To 
date, PET imaging of NOS expression has been focused on the clarification of nNOS 
function in neurological diseases [Pomper, et al. 2000, Zhang, et al. 1997]. PET imaging of 
nNOS was initially investigated with a 11C-labeled nNOS inhibitor, S-methyl-L-
thiocitrulline (MTICU) (FIG 11, 12) [Zhang, et al. 1997]. Biodistribution of 11C-MTICU 
gave a brain-to-blood ratio of 1:2 at 30 min postinjection. Uptake in the cerebellum (high 
nNOS expression) was 20% higher than that of the cortex or the brain stem (low nNOS 
expression). Blockage using 1 mg/kg of MTICU was able to reduce the uptake in the 
cerebellum and the cortex, but not in the brain stem. Study demonstrated the potential of 
11CMTICU as a potentially useful tracer in determining nNOS levels in vivo. In another 
report, two nNOS-selective PET tracers, AR-R 17443 [N-(4-(2-(phenylmethyl) (methyl)-
amino)ethyl)phenyl)-2-thiophenecarboximidamide)] and AR-R 18512 [(N(2-methyl-
1,2,3,4-tetrahydroisoquinoline-7-yl)-2 thiophenecarboximidamide)] were synthesized and 
evaluated in rodents and primates [Pomper et al. 2000]. Another strategy has been 
employed for iNOS imaging using antisense oligonucleotide with hybridization 
properties for iNOS mRNA using RT-PCR. The oligonucleotide was then labeled with 18F 
(FIG 12) [de Varies, et al. 2004]. Cellular uptake or efflux showed no selectivity for iNOS 
expressing cells. Thus PET imaging of NOS expression has not been very successful which 
is likely due to several reasons. First, the expression of NOS is in the cytoplasm. Although 
the radiolabeled NOS inhibitors usually have high affinity for NOS, they may not 
permeate through cell membrane efficiently which dramatically affects the tracer uptake. 
Second, the specificity of these NOS inhibitors may not be high enough for imaging 
applications; many of them can undergo nonspecific adsorption to other proteins such as 
albumin. Third, the stability of those tracers in vivo is a major concern. Uptake in the 
tumor or other targeted organs may not truly reflect the distribution of the intact tracer. 
Lastly, these NOS inhibitors are small molecules. Although replacing the 12CH3 with 
11CH3 will not change the chemical structure, in many cases this cannot be achieved. 
Recently, a novel NOS inhibitor design strategy, termed the “anchored plasticity 
approach,” may give rise to novel NOS inhibitors for PET imaging applications in the 
future [Garcin et al. 2008]. 
3.5.3 Imaging NOS expression with other techniques 
Besides optical and PET imaging, other techniques have been explored for NOS-related 
research, mainly electron microscopy and immunohistochemistry [Heinrich, et al. 2005, 
Lajoix, et al. 2006]. Electron microscopy was applied to visualize the subcellular localization 
of NOS in different cell organelles using gold particles conjugated with anti-NOS antibodies, 
which gave exquisite distribution information of NOS in cells. Immunohistochemistry also 
uses anti-NOS antibodies, easier to perform than electron microscopy yet the resolution is 
not as high. Both approaches are invasive and not suitable for in vivo imaging; however, the 
experimental findings are typically quite reliable and thus they can serve as ex vivo 
validation for in vivo imaging studies. 
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Fig. 11. (on left) Imaging NO with FRET. (A) Basic principles of FRET between CFP and 
YFP. CFP: cyan fluorescent protein; YFP: yellow fluorescent protein. (B) Pseudocolor images 
of the CFP/YFP emission ratio of the cell before (1570 s) and after addition of NOC-7, an 
NO-donating reagent that releases 2 mol of NO per mole. Adapted from reference [Hong et 
al. 2009] 
 
Fig. 12. (on right) Several NOS inhibiters and an antisense oligonucleotide for iNOS mRNA 
have been radiolabeled for PET imaging of NOS expression.Adapted from reference [Hong, 
et al. 2009] 
4. Biological applications of NO imaging 
Still development and applications of fluorescent agents in cell imaging and NO sensitive 
MRI contrast agents for in vivo physiological fMRI are in infancy. MRI imaging of NO based 
on nitrite concentration can detect physiological changes such as cerebral blood volume 
change in nonischemic spontaneously hypertensive rats [Caramia et al. 1998], increase in 
tumor blood flow and partial oxygen pressure after NO donor administration [Jordan et al. 
2000], NO production alteration in humans after a 30-min exposure to a 1.5 T magnetic field 
[Sirmatel, et al. 2007]. Interestingly, high magnetic strength can cause NO concentration 
fluctuations during a MRI scanning of NO-related diseases. 
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The major advantages of MRI include high resolution, good soft tissue contrast, wide 
availability, sufficiently large field-of-view, and the ability to provide both functional and 
anatomical information. Nitric oxide bioimaging has emerged as technique to visualize the 
intracellular metabolism based on redox reactions, mitochondrial oxidation and nitric oxide 
synthase enzyme NOSi [Anbar, 2000, Zhao, et al. 2009]. Recently, nitric oxide was invented 
as active mechanism to play role in vascular physiology in lungs, kidney, heart, brain, sex 
organs. Endothelial cell, smooth muscle cells, oxygenation and perfusion, hypoxia, ischemia 
are the possible targets of nitric oxide biotransformation. These physiological changes are 
likely to be visualized by nitric oxide bioimaging in real time manner and reviewed in the 
following sections. 
4.1 Cardiovascular and endothelial cell injury 
DAF-FM is useful tool to visualize the temporal and spatial distribution of intracellular NO. 
Endogenous ATP plays a central role in HTS-induced NOS in endothelial cell injury. 
Endothelial cNOS, a calmodulin-dependent enzyme is critical for vascular homeostasis and 
makes detectable basal level of NO production at low extracellular Ca2+. cNOS expression 
can be stimulated by Ca2+ while iNOS activity is Ca2+-independent. Actin microfilaments in 
primary artery endothelial cells (PAEC) regulates L-arginine transport and this regulation 
can affect NO production by PAEC, DAR-4M may be useful for bioimaging of samples that 
have strong autofluorescence [Lai, et al. 1994, Kojima, et al. 2001]  
4.2 Apoptosis in cells 
Apoptosis plays a key role in many pathological circumstances, such as neurodegenerative 
diseases. In these processes, the involvement of nitric oxide (NO) has been well established, 
and the ability of NO to exert cellular damage due to its reactive oxidative properties is 
perhaps the primary neurotoxic mechanism. Emerging evidences indicate that apoptosis 
contributes to neuronal death to explain neurodegeneration [Fujii et al. 1997]. The major 
biochemical change in activation of the cystein protease (caspase-3) was reported to execute 
apoptosis in the central nervous system disorders such as stroke, spinal cord trauma, head 
injury and Alzheimer’s disease [Green,1998, Nagata,1997 ]. Although numerous techniques 
have been described to evaluate apoptosis, these approaches involve invasive techniques 
and cannot provide detailed information about apoptosis in vivo [Anbar, 2000].  
4.3 Renal and cardiovascular imaging 
A new approach of irreversible responsive PARAmagnetic Chemical Exchange Saturation 
Transfer (PARACEST) for MRI contrast agents constituted a new type of agent for molecular 
imaging. A novel PARACEST MRI contrast agent, Yb(III)-(1,4,7,10-tetraazacyclododecane-
1,4,7-triacetic acid)-orthoaminoanilide (Yb-DO3A-oAA), was developed to image nitric 
oxide (NO). The agent exhibited two CEST effects at -11 ppm and +8 ppm chemical shifts, 
which were assigned to chemical exchange from amide and amine functional groups, 
respectively. This responsive PARACEST MRI contrast agent indicated the change in the 
presence of NO and O(2), which caused an irreversible disappearance of both PARACEST 
effects from MR images. This report highlighted the advantages of irreversible MRI contrast 
agents and demonstrated that large changes in PARACEST can be used to in vivo 
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biomedical applications in molecular imaging [Liu, et al. 2007]. In other study, the clinical 
detection of evolving acute tubular necrosis (ATN) and differentiating it from other causes 
of renal failure was performed. Herein, sodium magnetic resonance imaging (23Na MRI) was 
applied to study the early alteration in renal sodium distribution in rat kidneys 6 h after the 
induction of ATN combined with inhibition of nitric oxide and prostaglandin synthesis. 
Hence, 23Na MRI non-invasively quantified changes in the corticomedullary sodium 
gradient in the ATN kidney during morphologic tubular injury [Maril, et al. 2006]. Other 
newer application of 19F NMR spin-trapping technique for in vivo *NO detection was 
employed to elucidate the significance of *NO availability in animal models of hypertension. 
In vivo *NO-induced conversion of the hydroxylamine from fluorinated nitrosyl nitroxide 
(HNN) to the hydroxylamine of the iminonitroxide (HIN) was evidenced in hypertensive 
ISIAH and OXYS rat strains [Bobko, et al. 2005]. The NMR detected positive levels of 
nitrite/nitrate for in vivo evaluation of *NO production and provided the basis for in vivo 
*NO imaging [Kojima, et al. 2001, Kojima, et al. 2001].  
The cardiovascular ischemia in tissues generates the nitric oxide (NO). It is an enzyme-
independent mechanism of NO generation and more pathogenesis. So, the NO formation in 
mice after cardiopulmonary arrest could be imaged. Real-time measurement of NO 
generation was performed by detection of naturally generated NO-heme complexes in 
tissues using L-band electron paramagnetic resonance (EPR) spectroscopy. Measurements of 
NO generation were imaged on the intact animal at the levels of the head, thorax, and 
abdomen within 3 hours [Ueno, et al. 2002]. Very recently, nitric oxide was recognized as 
biomarker of vascular dysfunction in renal, clitoris and penile sex organs to detect the 
physiology [Ockalli, et al. 1999, Kakiailatu, 2000, Burnett, 2002, Barouch, et al. 2002, 
Hillebrandt, et al. 2009, Ciplak, et al. 2009, Gragasin, et al. 2004, Richards, et al. 2003]. The 
NO complexes were found to have maximum levels in lung, heart, and liver by three-
dimensional spatial mapping of the NO complex in the intact animal subjected to 
cardiopulmonary arrest. The images also confirmed the maximum NO formation in the 
lungs, heart, and liver [Kuppusamy, et al. 2001]. 
4.4 Calcium-imaging and NO-imaging 
The combined real-time bioimaging of calcium and nitric oxide with continuous 
electrophysiological intracellular recording has gained enormous interest. For intracellular 
monitoring by calcium imaging in cells, Fura-2 is a calcium-sensitive fluorescent probe. 
Using Fura-2, intracellular free calcium ion concentration ([Ca2+]i) of single neurons was 
measured [Richards, et al. 2003]. Calcium-imaging with Fura-2 was used to monitor and 
modulate the intracellular Ca2+ evoked by NMDA and AMPA in cultured hippocampal 
pyramidal cells [Keelan, et al. 1999] Calcium and NO play role in excitotoxic mitochondrial 
depolarization in the hippocampus [Berkels, et al. 2000]. The combination of NO bioimaging 
with calcium imaging may distinguish the temporal rise in NO and calcium to suggest that 
NO is being produced as a consequence of Ca2+ enhancement and Ca2+ induced NO 
Synthase activity). Recently, imaging intracellular calcium imaging was achieved together 
with NO imaging by using two monochromators DAF-2 and Fura-2 AM as excitation light 
source. The DAF-2 excited at 485 nm and Fura-2 AM excited at 340 nm [Berkels, et al. 2000]. 
The emission maximum of fura-2 is about 510 nm different while the emission maximum of 
DAF-2 is about 515 nm. By using dichroic or multichroic mirrors calcium and NO levels can 
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be measured simultaneously [Pittner, et al. 2003]. Other example of monochromator 
complex is DAQ and DAR-4M AM. These are calcium sensitive non-neurotoxic dyes with 
unique fluorescent patterns of DAQ (excitation 520 nm; emission 580 nm) and DAR-4M 
AM (excitation  550 nm; emission  580 nm). These can also combine with the calcium-
sensitive dye Fura-2 as potential tools in fluorescence microscopy.  
4.5 Kupffer cell NO bioimaging 
A new mechanism was reported in nonparenchymal cells based on Bcl-2/adenovirus EIB 
19-kDa interacting protein 3 (BNIP3), a cell death-related member of the Bcl-2 family, was 
upregulated in vitro and in vivo by nitric oxide (NO) downregulation of BNIP3 gene 
expression as one mechanism of hepatocyte cell death and liver damage. Authors proposed 
that inflammatory stresses can lead to the modulation of BNIP3 [Metukuri, et al. 2009].  
4.6 Combining electrophysiology and NO-imaging 
The calcium-imaging with electrophysiological recording was excitement in the 
hippocampus imaging art because of calcium accumulation in hippocampus pyramidal cells 
during synaptic activation [Regehr, et al. 1989]. Now a day, calcium-imaging combined with 
electrophysiological stimulation and recording has emerged as present state of art of 
calcium-signaling and intracellular free calcium ion concentration [Ca2+]i of single neurone. 
Moreover, little is understood how neuronal signals stimulate NO production. Potential 
applications of fluorescent NO indicators in bioimaging are to monitor NO in response to 
pharmacological manipulation using NO-donors, NOS substrate, and NOS or NOS isoform 
inhibitors as enhancers of NO production in vivo and in vitro [Moore, et al. 1997, Southan, 
et al. 1996]. Other emerging techniques of bioimaging by NO inhibitor are targeting the 
differential cofactor requirements of the various isoforms; pharmacological agents targeting 
the differential substrate requirements of cell expression of various isoforms of the NOS 
[Salerno, et al. 2002]. However, this approach suffers due to lack a marked isoform 
selectivity or direct affecting the arginine transport into cells, like NG-methyl-L-arginine (L-
NMA). Other example of NOS inhibitors such as 7-nitroindazole (7-NI), might have 
unexpected side-effects in neuronal tissues, since 7-NI interferes with monoamine oxidase 
[Castagnoli, et al. 1999, Desvignes, et al. 1999]. However, selective NOS-inhibitors together 
with fluorescent NO-imaging appear as useful tools for the investigation of the biological 
functions of the different NOS-isoforms in neuronal tissues [Chen, et al. 2001, Brown, et al. 
1999]. The combined NO-imaging with in vitro electrophysiology methods visualize the NO 
generation and NO distribution with localization of NO induced by neurotransmitter 
stimulations, e.g., NO formation after neuronal stimulation with NMDA, in normal synaptic 
transmission, in paired-pulse facilitation, in long-term depression or LTP. Thus, in a single 
preparation, the spatial distribution of NO after induction of hippocampal LTP has been 
evaluated [Schuppe, et al. 2002]. Main unsolved issues of precise time-point of NO release 
and selective NOS isoform-inhibitors in neuronal activity still remain to investigate before 
the combined fluorescent NO-imaging and electrophysiology method becomes an 
acceptable bioimaging tool. In near future, the researchers will thrive to combine 
electrophysiology with simultaneous calcium-imaging and NO-imaging to get better 
answers of the role and interaction of calcium and NO in physiological and pathological 
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neuronal processes with continuous monitoring the calcium and NO by dichroic or 
multichroic mirrors in synaptic plasticity.  
4.7 Alveolar cells 
Human alveolar macrophages and alveolar epithelium is the site of nitric oxide synthase-2 
(NOS-2) messenger ribonucleic acid (mRNA) and protein expression in alveolar wall in lung 
of patients with pulmonary malignancies. In the process of NO production, pro-
inflammatory cytokines interleukin (IL)-1ǃ, tumour necrosis factor (TNF)-, interferon 
(IFN)- or lipopolysaccharide (LPS) play significant role to induce the effect of human 
surfactant protein-A (SP-A) on IFN--mediated NOS-2 mRNA expression [Pechkovsky, et al. 
2002].  
4.8 Endothelial cells 
Kojima et al. 2001, reported NO bioimaging in cultured bovine aortic endothelial cells. The 
cultured bovine aortic endothelial cells were incubated with DAF-FM DA for 1 h for dye 
loading. After stimulation with bradykinin, the fluorescence intensity in the cells increased 
and that in the cytosol increased more than that in the nucleus. NO is produced in the 
cytosol, where NOS exists [von Bohlan, et al. 2002]. This observation implies that little of the 
produced NO diffuses into the nucleus or if it does diffuse into the nucleus little of it is 
oxidized there. The augmentation of the fluorescence intensity was suppressed by an NOS 
inhibitor. In conclusion, DAF-FM is a useful tool for visualizing the temporal and spatial 
distribution of intracellular NO. Kimura et al.2001, examined the effects of acute glucose 
overload on the cellular productivity of NO in bovine aortic endothelial cells (BAEC) using 
DAF-2. ATP induced an increase in NO production, assessed by DAF-2, mainly due to Ca2+ 
entry as shown in Figure 13. In contrast, the ATP-induced increase in DAF-2 fluorescence 
was impaired by glucose overload. The results indicate that glucose overload impairs NO 
production via the O2--mediated attenuation of Ca2+ entry. In addition, Kimura et al. 2000, 
examined in detail the mechanism by which mechanical stress induces NOS in endothelium. 
Hypotonic stress (HTS) induced ATP release, which evoked Ca2+ transients in BAEC. HTS 
also induced NOS, assessed by DAF-2 fluorescence. The results obtained indicate that 
endogenous ATP plays a central role in HTS-induced NOS in BAEC. Broillet et al. 2001, 
reported that Ca2+, Mg2+, or incident light promoted the reaction of DAF-2 and NO. 
However, Nagano et al. 2002, probed that the enhancement of fluorescence intensity was 
caused not by increasing the reaction rate between DAF-2 and NO but by promotion of NO-
releasing rate of NO donors. Endothelial NOS, a Ca2+/calmodulin-dependent enzyme, is 
critical for vascular homeostasis [Suzuki, et al. 2002]. To determine the signaling pathway 
for endogenous eNOS, Lin et al. 2000, directly measured NO production in bovine 
pulmonary artery endothelial cells (PAEC). Endothelial cells grown in a monolayer produce 
very low levels of NO which are below the detection range of traditional assays. Therefore, 
they employed DAF-2 DA to measure NO production in real-time. PAEC had detectable 
basal NO production which increased slightly after thapsigargin treatment in the presence 
of low extracellular Ca2+. In contrast, a large increase in NO production was detected in the 
presence of 4 mM extracellular Ca2+, suggesting that capacitative Ca2+ entry regulates wild-
type eNOS activity. Zharikov et al. 2001, investigated possible involvement of the actin 
cytoskeleton in the regulation of the L-arginine/NO pathway in pulmonary artery 
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endothelial cells (PAEC). DAF-2 DA was used for detection of NO in PAEC. They conclude 
that the state of actin microfilaments in PAEC regulates L-arginine transport and that this 
regulation can affect NO production by PAEC. Berkels et al. 2000, presented a new method 
to measure intracellular Ca2+ and NO simultaneously in endothelial cells. The method 
makes it possible to follow intracellular Ca2+ and NO distributions online and is sensitive 
enough to monitor changes of NO formed by the constitutive endothelial NOS. Franz et al. 
2000, reported DAR-4M AM applied to imaging of NO in bovine aortic endothelial cells 
using aminotroponiminates[Franz et al. 2000]. DARs are more photostable than DAFs. The 
fluorescence in cells was observed after stimulation with bradykinin (see Figure 14), which 
raises the intracellular Ca2+ level and thereby activates NOS, and this increase was 
suppressed by addition of an NOS inhibitor. DAR-4M should be useful for bioimaging of 
samples that have strong autofluorescence in the case of 490 nm excitation in which the 
intracellular pH may fall below 6. Hiratsuka et al. 2009, reported in vivo visualization of 
nitric oxide and intracellular inflammatory interactions among platelets, leukocytes, and 
endothelium following hemorrhagic shock and reperfusion.  
 
Fig. 13. Bright-field and fluorescence images of cultured bovine aortic endothelial cells 
loaded with DAR-4M AM. The upper images are the bright-field, the fluorescence, and the 
fluorescence ratio images at the start of measurement, respectively. The middle and the 
lower images are fluorescence ratio images at the indicated times after the start of 
measurement. The fluorescence ratio images indicate the ratio of the intensity to the initial 
intensity at the start. Adopted from reference Kimura, et al. 2001 
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Fig. 14. Fluorescence images of a rat brain slice loaded with DAF-2 DA. The fluorescence 
intensity is shown in pseudocolor. (Reproduced from reference Nagano, et al. 2002)  
4.9 Smooth muscle cells 
DAF-2 DA was applied to the imaging of NO in cultured rat aortic smooth muscle cells by 
using a fluorescence microscope equipped with fluorescence filters for fluorescein 
chromophores. Confocal laser scanning microscopy indicated that fluorescence was emitted 
from the whole cell body, including the nucleus. This implies that DAF-2 regenerated 
intracellularly by esterase is distributed throughout the whole cell. There was no indication 
of any cell damage caused by loading the dye. The results show that the fluorescence 
intensity in endotoxin- and cytokine-activated cells increased owing to DAF-2 T production 
from DAF-2 by reaction with NO. The fluorescence did not increase in inactivated cells, 
which did not produce NO. The probe is very useful for bioimaging of NO in cultured rat 
aortic smooth muscle cells. Itoh et al. detected DAF-FM T using reversed-phase high-
performance liquid chromatography with a fluorescence detector [Itoh et al. 2000]. This 
sensitive method enabled them to detect the spontaneous and substance P-induced NO 
release from isolated porcine coronary arteries, both of which were dependent entirely on 
the NOS activity in vascular endothelial cells. Furthermore, they obtained fluorescence 
images of cultured smooth muscle cells of the rat urinary bladder after loading with DAF-
FM DA. In the cells pretreated with cytokines, the fluorescence intensity increased with time 
after DAF-FM loading. In recent studies on imaging of nitric oxide in nitrergic 
neuromuscular neurotransmission suggested the new insight of molecular mechanisms in 
animal organs [Thatte, et al. 2009, Perrier, et al. 2009, Di Cesare Mannelli, et al. 2009]. 
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4.10 Brain and neuronal behavior 
Reif et al. 2009, reported the influence of functional variant of neuronal nitric oxide synthase on 
impulsive behaviors in humans. The biological functions of NO in the neuronal system remain 
controversial. Using DAF-2 DA for direct detection of NO, Nagano et al. 2002, examined both 
acute rat brain slices and organotypic culture of brain slices to ascertain NO production sites. 
The fluorescence intensity sensitive to Ca++ in the CA1 region of the hippocampus was 
augmented, especially after stimulation with NMDA, in acute brain slices. This NO production 
in the CA1 region was also confirmed in cultured hippocampus. Glutamate and NO were 
important mediators, since antagonists of both N-methyl-D-aspartate (NMDA) and NOS 
inhibitors were effective in attenuating neurotoxicity. This is the first direct evidence of NO 
production in the CA1 region as shown in Figure 4. There were also fluorescence cells in the 
cerebral cortex after stimulation with NMDA. Imaging techniques using DAF-2 DA should be 
very useful for the clarification of neuronal NO functions. Calcium sensitive fluorescent probe 
can monitor intracellular calcium by FURA-2. Combined calcium and NO together can be 
imaged by excitation light source (DAF-2) excited at 485 nm, and Fura-2 AM excited at 340 nm 
using dichroic or multichroic mirrors.DAQ, DAR-4M AM are other choices. NOS-II may be 
involved in Alzheimer’s disease as b-amyloid induces NOS-II expression in astrocytes 
Astrocytes which which can be potentiated by cytokines [Vodovotz et al. 1996].  
DAF-FM DA was also applied to imaging of NO generated in rat hippocampus slices by 
exposure to an aglycemic medium [Reif et al. 2009]. NO production was observed mainly in 
the CA1 area and was dependent on the concentration of O2. During exposure to an anoxic-
aglycemic medium, NO was hardly produced while marked elevation of intracellular Ca2+ 
was observed. Production of NO increased sharply as soon as the perfusate was changed to 
the normal medium. These results suggest that NOS is activated after reperfusion rather 
than during ischemia. ROS and NO are important participants in signal transduction that 
could provide the cellular basis for activity-dependent regulation of neuronal excitability 
[Yermolaieva, et al. 2000]. In young rat cortical brain slices and undifferentiated PC 12 cells, 
paired application of depolarization/agonist stimulation and oxidation induces long-lasting 
potency of subsequent Ca2+ signaling that is reversed by hypoxia. This potency critically 
depends on NO production and involves cellular ROS utilization. Using the fluorescent dye 
DAF-2, NO production was measured in PC 12 cells during depolarization or histamine 
application [Yermolaieva, et al. 2000]. Application of 100 µM histamine induced a significant 
increase in NO production. The crucial role for NO in oxidative potentiation of Ca2+ 
signaling triggered by pairing of electrical/agonist stimulation and oxidation demonstrated 
here provides an insight into the cellular mechanisms involved in neuronal developmental 
plasticity. NO could influence its effectors by stimulating the cGMP-dependent signaling 
pathway and/or by acting as a weak radical. Perrier et al. 2009, reported the effect of 
uncoupling endothelial nitric oxide synthase on calcium homeostasis in aged porcine 
endothelial cells in heart. In other report, Sergeant et al. 2009, reported the spontaneous Ca2+ 
waves in rabbit corpus cavernosum were modulated by nitric oxide. Role of cGMP was 
crucial in regulation of calcium dependent neuroactive energy changes. 
4.11 Ion channels 
Most voltage-gated Na+ channels are almost completely inactivated at depolarized 
membrane potentials, but in some cells a residual Na+ current is seen that is resistant to 
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inactivation. The biological signaling mechanisms that regulate the persistence of Na+ 
channels are not well understood. Ahern et al. 2000, showed that in nerve terminals and 
ventricular myocytes, NO reduces the inactivation of Na+ current. This effect was 
independent of cGMP and blocked by N-ethylmaleimide. Thus, ROS act directly on the 
channel or a closely associated protein. Application of ionomycin to raise the intracellular 
Ca2+ concentration in myocytes activated NOS. The NO produced in response to ionomycin 
was detected with DAF-2 DA. They concluded that NO is a potential endogenous regulator 
of persistent Na+ current under physiological and pathophysiological conditions. Choi et al. 
2000, reported that the NMDA receptor (NMDAR)-associated ion channel is modulated not 
only by exogenous NO, but also by endogenous NO. They examined inhibition of NMDAR 
responses by endogenous NO to determine the underlying molecular mechanism. For this 
purpose, HEK 293 cells transfected with nNOS were transiently transfected with wild-type 
NR1/NR2A or mutant NR1/NR2A (C399A) receptors. NMDA responses were monitored 
by digital Ca2+ imaging with fura-2. Production of endogenous NO by these HEK-nNOS 
cells was measured with DAF-2. It was concluded that endogenous S-nitrosylation may 
regulate ion channel activity.  
4.12 Fertilization and developmental biology 
Kuo et al. 2000, demonstrated that NO is necessary and sufficient for egg activation at 
fertilization. The early steps that lead to the rise in Ca2+ and egg activation at fertilization are 
unknown but are of great interest, particularly with the advent of in vitro fertilization 
techniques for treating male infertility and whole-animal cloning by nuclear transfer. They 
showed that active NOS is present at high concentration in sperm after activation by the 
acrosome reaction. An increase in nitrosation within eggs is evident seconds after 
insemination and precedes the Ca2+ pulse of fertilization. They used DAF-2 DA for detection 
of NO. It was concluded that NOS- and NO-related bioactivity satisfy the primary criteria of 
an egg activator, i.e. they are present in an appropriate place, active at an appropriate time, 
and necessary and sufficient for successful fertilization.  
4.13 Inflammation 
NO plays important roles in inflammatory processes. Lopez-Figueroa et al. 2000, examined 
whether changes in NOS mRNA expression lead to similar temporal and anatomical 
changes in NO production in an experimental model of CNS inflammation. iNOS mRNA 
expression was analyzed 2, 4, 6, and 24 h after intracerebroventricular (icv) injection of 
interleukin-1ǃ or the vehicle. Increased expression of iNOS mRNA was observed 
surrounding the microinjection site and meninges. Using DAF-2 DA for the direct detection 
of NO production, they observed a significant increase in NO production after 4 and 6 h. 
They conclude that increase in iNOS mRNA following icv administration of IL-1ǃ leads to 
increases in NO production. They proposed that the DAF-2 DA method can be used as a 
potential marker in the diagnosis of CNS inflammation. MRI of NO is very useful because 
NO is available at high concentrations in millimolar levels in immune-related diseases (e.g., 
inflammation).Terashima et al. 2010, reported in vivo detection of iNOS expression in 
murine carotid lesions by biuoluminescence may provide a valuable approach for 
monitoring vascular gene expression and inflammation in small animal models. The phasic 
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nature of inflammation is also associated with a decrease in NOS activity. NOS inhibitors 
are effective at alleviating pain and have disease modifying effects. Induction of NOS-II is 
seen in models of septic shock. NOS-II inhibitors (dexamethasone) prevent hypotension and 
decrease in PO2. 
 
Fig. 15. Optical imaging of iNOS expression. (A) Fluorescence imaging of iNOS in living 
cells. Left: cells were induced for iNOS expression; Right: cells were not induced for iNOS 
expression. (B) Bioluminescence signal from the knee joints (circle) indicates iNOS 
expression following inflammation induction. Adapted from reference [Panda, et al. 2000]. 
4.14 Adrenal zona glomerulosa 
Adrenal zona glomerulosa (ZG) cells do not contain NOS. Hanke et al. 2000, conferred 
endothelial NOS activity upon adrenal ZG cells through transduction with a recombinant 
adenovirus encoding the endothelial NOS gene (AdeNOS) to determine the effect of 
endogenous NO on aldosterone synthesis. AdeNOS-transduced cells exhibited DAF-2 DA 
fluorescence, which was blocked by pretreatment with an NOS inhibitor. In conclusion, 
adenovirus-mediated gene transfer of eNOS in ZG cells results in the expression of active 
endothelial NOS enzyme, and this endogenous NO production by ZG cells decreases 
aldosterone synthesis.  
4.15 Bone marrow stromal cells 
Gorbunov et al. 2000, reported that using the reverse transcription-polymerase chain 
reaction and immunofluorescence analysis of murine bone marrow stromal cells after -
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irradiation doses of 2-50 Gy stimulated the expression of iNOS. The activation of iNOS was 
accompanied by an increase in the fluorescence of DAF-2 and accumulation of 3-
nitrotyrosine within cellular proteins in a dose-dependent manner.  
4.16 Mitochondria 
NO has been implicated in the modulation of mitochondrial respiration, membrane 
potential, and subsequently apoptosis. Although the presence of mitochondrial NOS was 
reported while there is no direct evidence in vivo of the presence of NO within 
mitochondria. Using DAF-2 DA, Lopez-Figueroa et al. observed NO production in PC 12 
and COS-1 cells by conventional and confocal fluorescence microscopy [Lopez-Figueroa, et 
al. 2000]. The subcellular distribution of NO production is consistent with the presence of a 
mitochondrial NOS.  
4.17 Retina 
In the retina, NO functions in network coupling, light adaptation, neurotransmitter receptor 
function, and synaptic release. Neuronal NOS is present in the retina of every vertebrate 
species so far investigated. However, although nNOS can be found in every retinal cell type, 
little is known about the production of NO in specific cells or about the diffusion of NO 
within the retina. Blute et al. 2000, used DAF-2 to image real-time NO production in turtle 
retina in response to stimulation with NMDA. In response to NMDA, NO was produced in 
somata in the ganglion cell and inner nuclear layers, in synaptic boutons and processes in 
the inner plexiform layer, in processes in the outer plexiform layer, and in photoreceptor 
inner segments. They concluded that NO may function at specific synapses, modulate gene 
expression, or coordinate events throughout the cell. Matsuo et al. 2000, reported that basal 
NO production is enhanced by hydraulic pressure in cultured human trabecular cell. He 
measured the intracellular NO level in real-time using DAF-2.  
4.18 Drosophila 
Wingrove and O'Farrell 1999, reported that Drosophila utilizes components of the NO/cGMP 
signaling pathway to respond to hypoxia. Hypoxic exposure rapidly induced exploratory 
behavior in larvae and arrested the cell cycle. These behavioral and cellular responses were 
diminished by an inhibitor of NOS and by a polymorphism of cGMP-dependent protein 
kinase. Regions of the larvae that specialize in responding to hypoxia should express 
significant levels of the activities involved. They used DAF-2 DA to define possible foci of 
function. DAF-2 DA stained the pouch of tissue surrounding the anterior spiracles as well as 
neuronal-like processes within the pouch. This staining near the openings of the tracheal 
system is interesting because the location is consistent with a possible role in governing the 
opening of the spiracles to increase access to oxygen. DAF-2 DA is useful for clarification of 
response mechanisms to hypoxia.  
4.19 Plants 
Leaves and callus of Kalanchoe daigremontiana and Taxus brevifolia were used to investigate 
NO-induced apoptosis in plant cells [Huang, et al. 2000]. NO production was visualized in 
cells and tissues with DAF-2 DA. The NO burst preceded a significant increase in nuclear 
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DNA fragmentation and cell death. L-NMMA significantly decreased NO production and 
apoptosis in both species. Pedroso et al. 2000a, 2000b concluded that NO is involved in DNA 
damage leading to cell death and proposed a potential role of NO as a signal molecule in 
these plants. Foissner et al.2000, used DAF-2 DA, in conjunction with confocal laser 
scanning microscopy, for in vivo real-time imaging of an elicitor-induced NO burst in 
tobacco. A growing body of evidence suggests that NO, an important signaling and defense 
molecule in mammals, plays a key role in activating disease resistance in plants, acting as a 
signaling molecule and possibly also as a direct antimicrobial agent. The results revealed 
additional similarities between plant and animal host responses to infection.  
5. NO/NOS bioimaging: Future prospects 
The existing techniques based on quenching spin trap or paramagnetic heavy metals pose a 
concern of contrast agent toxicity with limitations of event capturing to generate NO image 
of isolated cells by EPR or in vivo body image by MGD enhanced MRI. However, unique 
role of short lived NO molecule in the cell is peculiar to give insight of rapid ionic 
regulatory mechanisms such as calcium, sodium dependent signaling events including 
dietary effects, antimicrobial therapy on inflammation, angiogenesis and hypoxia reported 
in last three years [Manuel, et al. 2002, Palombo, et al. 2009]. To date, the main imaging 
modalities for visualization of NO include fluorescence and bio/chemiluminescence optical 
imaging, electron paramagnetic resonance (EPR) imaging, and MRI. cNOS has been mainly 
investigated using optical and PET imaging. Paper has presented a progress to date on 
multimodality imaging of NO and addressed the future research directions and obstacles of 
NO imaging. Other major developments are expected in design of robust imaging hardware 
with improved image generating capability and highly sensitive to the rapid changes of 
NO/NOS molecular EPR signal and MRI frequency with time. In this direction, active 
research efforts suggest the development and availability of less toxic ion sensitive contrast 
agents attached with EPR and MRI visible molecules as labels sensitive to fluorometric and 
magnetic resonance techniques respectively. It is attributed that cytochromes are best 
candidates as fluorochromic agents while lipopolysaccharides and carbamates with 
paramagnetic agents are potential as MRI contrast agents. More likely, fast imaging 
techniques such as parallel phase array, SENSE, FISP MRI imaging, xenon based 
PARACEST techniques may be available to capture rapid NO changes or distribution 
associated with metabolic short lived events such as oxygen sensitivity, sodium sensitivity 
in the intact tissue. In future, advances in ionic ratiomatric techniques will be available to 
capture the short living NO molecular distribution in cells as real-time events associated 
with motion. Still major issues to resolve are:  
 lack of NO sensitive EPR or MRI contrast agent to generate quicker and enough MRI or 
EPR signal visible as image;  
 the EPR and MRI signals are not true representative of NO concentrations;  
 the images generated from MRI visible paramagnetic ions or EPR visible spin trap 
agents may represent several physical and molecular events sensitive to attached NO 
quenching carbamates or polysaccharides for MRI and cytochrome proteins for EPR.  
The biggest disadvantage of MRI is its low molecular sensitivity. The need for a high dose of 
imaging agents (typically more than 100 mM injection) undoubtedly raises major concerns 
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about the potential toxicity caused by such studies. Lastly, relatively long data acquisition 
time is typically needed to generate a detectable MR signal in MR imaging. Since the lifetime 
of NO and/or related species is usually short, the accuracy of MRI measurement of NO 
concentration is questionable. After these issues are resolved, it will need sequence of 
investigations to calibrate linearity of NO concentration and image signal intensity, image 
reproducibility, image component analysis, signal measurement accuracy and precision of 
NO sensitive imaging techniques as shown in Table 4.  
 
Target Modality Resolution Sensitivity Penetration Clinical potential 
NO Optical ++++ ++++ + Low 
NO EPR ++ ++++ +++ Medium 
NO MRI +++ + ++++ Medium 
NO PET ++ ++++ +++ Medium 
cNOS Optical ++++ +++ ++ Low 
cNOS PET +++ ++++ ++++ Medium-High 
Table 4. Comparison of molecular imaging of NO and cNOS expression 
5.1 Real-time NO imaging 
Nitric oxide (NO) is a small uncharged free radical abundant in nanomolar quantities that is 
involved in diverse physiological and pathophysiological mechanisms.  
 When generated in vascular endothelial cells, NO plays a key role in vascular tone 
regulation and EPR/optical/MRI visible signals visualize the vascular physiology 
(induced fitting of L-arginine specific NOS active site) as prosposed by author to inhibit 
NOS and low NO production shown in Figure 5.  
In this direction, short lived NO specific amplifier-coupled fluorescent indicator was 
reported to visualize physiological nanomolar dynamics of NO in living cells (detection 
limit of 0.1 nM)[Ueno, et al. 2002, Burnett, et al. 2002]. An amplifier-coupled fluorescent 
indicator visualizes NO in single living cells. Its domain structures are sGCǂ, sGCǃ, CGY, 
sGCǂ-CGY, and sGCǃ-CGY. This genetically encoded high-sensitive indicator revealed that 
≈1 nM of NO was enough to relax blood vessels [Ueno, et al. 2002, Burnett, et al. 2002, 
Barouch, et al. 2002, Hillebrand et al. 2009, Ciplak, et al. 2009, Gragasin, et al. 2004]. The 
nanomolar range of basal endothelial NO thus revealed appeared to be fundamental to 
vascular homeostasis. A fuorescent probe, 1,3,5,7-tetramethyl-2,6-dicarbethoxy-8-(3,4-
diaminophenyl)-diXuoroboradiaza-s-indacence (TMDCDABODIPY), produced real-time 
image NO of PC12 cells, Sf9 cells and human vascular endothelial cells in the presence of L-
arginine with inverted fuorescence microscope [Manuel, et al. 2002]. NO production in the 
cells was successfully captured and imaged with improved temporal and spatial resolution. 
The bioimaging applications of TMDCDABODIPY as a fuorescent imaging probe for NO in 
living cells was compared with the other fuorescent imaging probes for NO. The 
TMDCDABODIPY had the advantages of shorter reaction time, higher photostability and 
minimal background. The study has indicated that TMDCDABODIPY-based fuorescence 
microscopy may be a promising approach for NO-related pathological and physiological 
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studies [Hiratsuka, et al. 2009]. A recent review highlighted the possibilities if nitric oxide 
bioimaging becomes reality as clinical imaging tool [Hong, et al. 2009]. Current state-of-the-
art multimodality imaging may detect NO and NOS enzyme expression [Matter et al. 2004, 
Zhang, et al. 2011]. Optical (fluorescence, chemiluminescence, and bioluminescence), 
electron paramagnetic resonance (EPR), magnetic resonance (MR), and positron emission 
tomography (PET) noninvasive imaging techniques may reveal the biodistribution of NO or  
  
Fig. 15. (on top) Formation and release of NO in tissues is shown. No is trapped by 
Fe2+(MGD)2 to make MRI/EPR visible trap NO-(MGD)2-Fe3+. (in middle row)The figure 
represents how different levels of Nitric oxide (1) activate cytosolic guanylate cyclase (2) and 
thus elevate intracellular levels of cyclic GMP (3 and 4) as secondary messenger. The cyclic 
GMP stimulates response (5) in different tissues and nitric oxide can be detected as 
biomarker of tissue pathology.(at bottom) The relation of released NO across the membrane 
is shown with different biological and physiological changes to generate EPR and MRI 
signal visible by imaging techniques. Notice the NO regulation by enzyme guanylate cyclase 
over intracellular responses (cell injury, inflammation etc.) sensitive to spin trap MRI/EPR 
image signals. A proposal of multimodal nitric oxide imaging is shown for development of 
multimodal spin trap applicable in imaging. 
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NOS in living subjects with high fidelity which will greatly facilitate scientists and clinicians 
in the development of new drugs and patient management[Oliveira, et al. 2010, Payne, et al. 
2010]. Lastly, novel NO/NOS imaging agents with optimal in vivo stability and suitable 
pharmacokinetics such as pteridines, imidazoles, quinolines for clinical translation will 
benefit in patient management [Payne, et al. 2010, Bonnefous, et al. 2009].  
Imaging of NOS expression mainly relies on labeling high affinity, preferably also high 
specificity, NOS inhibitors with optimal membrane permeability and pharmacokinetics. Of 
all the fluorescence imaging agents for NO, the DAFC compounds are the most widely used. 
The requirement of oxygen restricts their applicability in cancer-related NO imaging to a 
certain extent, although some have been tested for NO imaging during tumor angiogenesis 
[Kashiwagi, et al. 2005]. Copper-based fluorescent compounds do not require oxygen for 
NO imaging, yet the stability and toxicity of those compounds are questionable. FRET-based 
NO imaging is a clever approach, yet it is too technically challenging to be widely available 
and useful. With spin-trapping technology, EPR imaging of NO can be quite accurate, yet it 
is not applicable for clinical studies due to many reasons. MRI can have high resolution and 
large field-of-view for potential clinical imaging studies, yet it is usually quite slow in data 
acquisition and the intrinsic low sensitivity makes molecular MRI unlikely to succeed in the 
clinic. NOS imaging is also important in elucidating NO-related physiological and 
pathological processes. NOS imaging has not been well studied to date. To the best of our 
knowledge, no clinical studies of NO or NOS imaging have been reported. Whether 
NO/NOS imaging can help and improve patient management remains to be demonstrated 
in the future. The deregulation of iNOS in melanoma has been correlated directly with poor 
survival [Madunapantula, et al. 2008] and NOS expression in patients with neurological 
disorder has been studied [Broholm, et al. 2004]. Given the fact that NO and NOS plays 
diverse roles in many diseases such as inflammation, neurodegeneration, cancer, and 
vascular malfunctions, further understanding of the disease mechanisms and clarification of 
the temporal/ spatial NO/NOS expression are certainly very important in patient 
management. Whether imaging NO or NOS is more relevant depends primarily on the 
disease. eNOS and nNOS typically only produces low levels of NO; therefore, imaging NO 
is expected to be more difficult than imaging the NOSs themselves. On the other hand, 
iNOS can produce high concentrations of NO in immunological processes and/or cancer; 
hence imaging NO may be more desirable in these scenarios. Granted that NO imaging is 
more relevant since it directly affects the physiological and pathological processes, imaging 
of NO may not always be feasible and imaging NOS expression (as an alternative) can 
provide valuable insights. The notion that nitrite reduction can also serve as a possible 
source of biologically relevant NO tilted the balance toward NO imaging [Bryan, 2006]. 
Nitrite reduction to NO can occur via several routes involving enzymes, proteins, vitamins, 
or even simple protons [Galdwin, 2004, Lundberg, et al. 2005]. Nitrite is now under active 
investigations in physiology, pathophysiology, and therapeutics. The ideas that nitrite can 
be a “storage” form of NO and the possible importance of dietary nitrite are two vibrant 
research areas today. Similar to the important role of L-arginine for optimal NOS activity, 
nitrite may emerge as an essential nutrient. This pathway may serve as a backup system for 
NO generation in conditions such as hypoxia, in which the NOS/L-arginine system is 
compromised. We envision that imaging NO and NOS in the same system will undoubtedly 
give a more thorough picture in understanding the functions of NO and NOS. For potential 
clinical translation of NO/NOS imaging probes, PET tracers have the best chances of 
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success. Each imaging modality has its advantages and disadvantages in terms of 
sensitivity, spatial resolution, temporal resolution, probe availability, and cost [Massoud, et 
al. 2003]. With the development of hybrid imaging systems such as PET/CT, SPECT/CT, 
and PET/MRI Catana et al. 2006; Sharma, 2002, 2008, 2011;Townsend, et al. 2002], a 
multimodality approach may offer synergistic advantages over any single modality alone in 
the future. 
6. Conclusion 
Nitric oxide (NO) in vivo image visualizes the distribution of NO using the ‘‘spin-trapping’’ 
technique. Available NO visualizing chemical probes combined with the spin traps and 
fluorescent dyes are promising. Physiological mechanisms of NO production by NOS and 
role of NOS gene expression altered by NOS inhibitors is illustrated. Scope: Different 
multimodal contrast mechanisms are introduced using nitrosyl-iron complexes as MRI-PET 
signal intensity enhancers and fluorescent or bioluminescent NO visualizing cheletropic 
trap agents. NO synthase enzyme is the source of NO formation in presence of competitive 
inhibitor N-monomethyl-L-arginine in the tissues.  
 General Significance: NO makes stable paramagnetic with N-methyl-D-glucamine 
dithiocarbamate (MGD), as (MGD)2-Fe(II)-NO metal complex in vivo by spin trapping 
and may serve as effective EPR and/or MRI contrast agent than other less stable 
nitrogen containing radicals, such as bound nitric oxides. MRI spin-trapping induces 
the magnetic resonance relaxation changes of neighboring protons and visualizes 
spatial distributions of NO free radicals in pathologic organs and tissues but not 
confirmed. Other paramagnetic NO-Fe-dithiacarbamate metal complexes serve as 
contrast agents in EPR bioimaging. Recently, real time physiological in vivo monitoring 
using tissue physical properties such as fluorescence and magnetic resonance in tissues 
is revisted to visualize nanomolar range of nitric oxide mapping.  
 Major conclusions: 1. More applications of NO bioimaging and fluorescent probes are 
emerging in imaging apoptosis, vascular imaging, smooth muscle cells, 
neurodegeneration, calcium channel imaging and endothelial stress. 2. The status of NO 
production by NOS in cells gives insight of inflammation, fertilization, mitochondrial 
oxidation injury, bone structure and adrenal gland and retina. 3. The real time NO 
imaging application is emerging in animals and plants. 
 Major highlights:  
 Nitric oxide bioimaging is emerging as rapid noninvasive multimodal molecular 
imaging techniques by fluorescent, MRI, PET, optical bioimaging for wider 
applications;  
 Significant progress is made to explain the mechanism of multimodal NO spin trap 
contrast agent enhanced MRI and fluorescent bioimaging;  
 Both MRI and fluorescent contrast agents may serve as potential MRI/fluorescent 
multimodal spin traps as well as contrast agents in clinical or bioimaging;  
 NO sensitive MRI of vital soft tissues is major achievement to visualize very short 
lived NO in real time manner. 
 Development of NOS inhibitors or NO production suppressors and in vivo 
NO/NOS evaluation is a booming industry in diagnostics of stroke, sepsis, 
neurodegeneration, inflammation and new drug discovery.  
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Spin trap contrast agents may enable the simultaneous EPR-MRI and fluorescent imaging of 
NO distribution in the organs and tissues in muscle vascular system, retina, adrenal gland, 
brain, bone marrow to monitor intracellular metabolic events such as apoptosis, 
inflammation, nerve activation and calcium ions etc. To our knowledge, there are no reports 
of successfully imaging or detecting free radicals such as NO in vivo clinical imaging. Due 
to short lifetime and rapid diffusion of NO in tissue, it is a challenge to devise any effective 
relaxation enhancement mechanism(s) for noninvasive clinical imaging. NMR spin trapping 
may serve to overcome these problems of NO short lifetime and diffusion to some extent.  
7. Appendix 1: Protocols on NOS and NO* radical detection 
Source: Cai H., Dikalov S, Griendling K.K., Harrison, D.G.(2007) Detection of reactive 
oxygen species and nitric oxide in vascular cells and tissues. Chapter 20 In: Methods in 
Molecular Medicine, Vascular Biology Protocols. Editor: Sreejayan N. and Ron J., Humana 
Press Inc. Totowa, NJ. Pp 293-311. 
Electronic configuration in NO* with 11 valence electrons:  
(K2K2)(2sb)2(2s*)2(2pb)4(2pb)2(2p*)1  
Detection of Nitric Oxide Radical 
It has been challenging to detect nitric oxide radical (NO) directly from biological samples. 
NO “production” is measured by NO synthase activity using the L-arginine conversion 
assay or NO metabolites nitrite and nitrate using the Griess reagent. New methods are 
NO-selective electrode and ESR represent specific and quantitative assays for detection of 
functional NO. 
Materials needed:  
1. NO-Specific Microelectrode 
Nafion and o-PD coated carbon electrode can directly detect NO in the low 
micromolar range. 
2. ESR with NO-Specific Spin Traps 
Dithiocarbamate (DTC), N-methylglucamine dithiocarbamate (MGD) detect 
extracellular NO*, and diethyldithiocarbamate (DETC) trap and detect the NO* in 
cellular lipid membrane.  
iron-MGD and iron-DETC. 
3. ESR measurement: 
 Endothelial or vascular smooth muscle cells. 
 Modified Krebs/HEPES buffer (see Subheading 2.1.1.2.). 
 Cyclic hydroxylamine CPH or 1-hydroxy-3-methoxycarbonyl-2,2,5,5-
tetramethylpyrrolidine 
 (CMH) stock solution (10 mM) (Alexis Biochemicals, San Diego, CA, 
 USA) in modified Kreb’s/HEPES buffer containing metal chelator, 25–50mM 
 deferoximine, and 3 5mM DETC. This stock solution should be de-oxygenated by 
 nitrogen gas continuously to maintain low background oxidation of the spin traps. 
 Lysis buffer containing protease inhibitors: 50mM Tris–HCl buffer, pH 7.4, 
 containing 0.1mM ethylenediamine tetraacetic acid (EDTA), 0.1mM ethylene 
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 glycol tetraacetic acid (EGTA), 1mM phenylmethyl sulfonyl fluoride, 2mM 
bestatin, 1mM pepstatin, and 2mM leupeptin. 
 NADPH (0.2 mM). 
 Xanthine (0.1 mM). 
Detection of Nitric Oxide Radical 
NO-Specific Microelectrode 
 Carbon fiber electrodes (100µm length and 30µm outer diameter; Word Precision 
 Instruments, Sarasota, FL, USA). 
 o-PD solution (in 0.1M PBS with 100µM ascorbic acid). 
 Nafion (5% in aliphatic alcohols; Sigma-Aldrich). 
 Modified Kreb’s/HEPES buffer. 
 Axopatch 200B amplifier (Axon Instruments, Union City, CA, USA). 
 Silver/silver chloride reference electrode. 
Iron-DETC for Trapping of NO 
 Culture endothelial cells. 
 Saline (0.9% NaCl). 
 Fe2+(DETC)2 : FeSO4·7H2O, 4.45 mg/10 ml for 1.6 mmol/l stock and DETC, 7.21 mg/10 
ml for 3.2 mmol/l stock. 
 PBS. 
 Modified Kreb’s/HEPES buffer. 
 Ferrous sulfate (4 mM). 
 N-methyl-d-glucamine dithiocarbamate MGD (20 mM). 
Methods: 
Detection of Nitric Oxide Radical 
NO-Specific Microelectrode  
 Coat bare carbon fiber electrodes (100µm length and 30µm outer diameter; Word 
 Precision Instruments) with nafion and o-PD. Coat with freshly made o-PD solution at 
constant potential (+0.9V vs. Ag/AgCl reference electrode) for 45 min. Dip in nafion 
solution for 3 s and dry for 5 min at 85°C. The nafion-coating cycle should be repeated 
10–15 times. 
 Culture endothelial cells on 35-mm dishes or prepare fresh tissue samples in freshly 
made modified Kreb’s/HEPES buffer. 
 Place the electrode tip at the surface of an individual cell, endocardium, or lumen of 
blood vessels, and then withdraw precisely 5µm. 
 Record NO-dependent oxidation currents (voltage clamp mode, hold at 0.65 V, 
approximately the voltage for peak NO oxidation) immediately after addition of 
agonists using an Axopatch 200B amplifier (Axon Instruments). A silver/silver chloride 
reference electrode is used. Use pCLAMP 7.0 program (Axon Instruments) for delivery 
of voltage protocols and data acquisition and analysis. 
 Calculate NO concentrations from a standard curve obtained using dilutions of de-
oxygenated, saturated NO* gas solutions. 
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Iron-DETC Protocol for Intracellular Trapping of NO 
 Culture endothelial cells on 100-mm Petri dishes or prepare vascular segments (6–12, 2-
mm vessel segments). 
 Bubble freshly prepared saline (0.9% NaCl) with nitrogen gas to remove oxygen. 
 Aspirate media and rinse cells with warm PBS once, add 1.5 ml modified 
Kreb’s/HEPES buffer with or without desired agonists, then mix Fe2+(DETC)2, and 
immediately add to culture dish (500µl of each solution, final volume 2.0 ml). 
 Incubate in cell culture incubator for desired period for cumulative trapping of NO. 
 Aspirate buffer, gently collect cells into a 1-ml insulin syringe, snap freeze in liquid 
nitrogen, then transfer sample column into a finger dewer, and capture Fe2+(DETC)2–
NO signal using ESR at the following settings: 
 Bruker EMX: Field sweep, 160 G; microwave frequency, 9.39 GHz; microwave power, 
10MW; modulation amplitude, 3 G; conversion time, 2621 ms; time constant, 328 ms; 
modulation amplitude, 3 G; receiver gain, 1×104; and four scans. 
 Miniscope 200: Biofield, 3267; field sweep, 100 G; microwave frequency, 9.78 GHz; 
microwave power, 40 mW; modulation amplitude, 10 G; 4096 points resolution; and 
receiver gain, 900. 
Iron-MGD Protocol for Extracellular Trapping of NO 
 Culture endothelial cells on 100-mm Petri dishes or prepare vascular segments (6–12, 2-
mm vessel segments). 
 Bubble freshly prepared saline (0.9% NaCl) with nitrogen gas to remove oxygen, and 
then make stock solutions of FeSO4·7H2O, 4 mM, and MGD, 20 mM. 
 Prepare stock solutions of Fe2+MGD by mixing FeSO4 and MGD at the ratio of 1:5 or 
1:10 (final Fe concentration: 0.5 mM). 
 Aspirate media and rinse cells with warm PBS once, add 1.5 ml modified 
Kreb’s/HEPES buffer with or without desired agonists, then mix Fe2+(MGD)2, and 
immediately add to culture dish. 
 Incubate in cell culture incubator for desired period for cumulative trapping of NO. 
 Collect 1 ml of post-incubation supernatant into a 1-ml insulin syringe and snap freeze 
in liquid nitrogen, then transfer sample column into a finger dewer, and capture 
Fe2+MGD–NO signal using ESR settings as described above for Fe2+(DETC)2. 
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